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Abstract 
Race and ethnicity are risk factors for prostate cancer. In the United States, African 
American men have the highest rate of mortality followed by Caucasians, and Asian 
Americans.  The effects of race and ethnicity on prostate cancer are also reflected in 
different frequencies of ETS family fusion in different groups. ETS family fusions is 
the most common alteration in prostate cancer of Caucasian men at a frequency of 
~50%, however, they are lower in African Americans and Chinese at 20-30%. Most of 
the genomic prostate cancer studies are focused on cohorts of European ancestry, 
leaving minority groups underrepresentation. Furthermore, in racial mixing, the ethnic 
contribution to risk is unclear. Sardinia population is an isolated Mediterranean 
population, and a purported refuge population of Neolithic ancestry with much lower 
incidence of prostate cancer than that in mainland Europe. Here, we conducted a 
genomic prostate cancer genomic study on a Sardinia cohort diagnosed with local 
prostate cancer. We identified a novel germline risk mutation ARSD-G320D occurring 
in 53 percent of the patients, somatic UGT family amplifications which occurred in 
20% the patients, a novel in-frame fusion BTBD7-SLC2A5 occurred in 12 % of the 
patients. In addition, we pointed out that IRF8 deletion at 16q24.2 is a candidate 
driver in prostate cancer and patients with IRF8 deletion have worse prognosis. Our 
data revealed similarities and disparities in genomic alterations of prostate cancer 
between Sardinians and other ethnic groups. As well we have conducted a study based 
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on Chinese prostate cancer cohort and have seen greater molecular disparities from 
TCGA cohort than in the Sardinian prostate cancer cohort. In Chinese cohort we have 
identified 37 genes significantly mutated and 20 of them have not implicated in 
prostate cancer in Caucasian and reveals a set of genomic markers that may inform 
the ethnic disparities. 
 
ChapterⅠ.Introduction 
1. Incidence, mortality of prostate cancer worldwide 
Prostate cancer is the most common and fifth fatal cancer in men worldwide[1]. In 
2012, an estimated of 1.1 million people were diagnosed with prostate cancer, and 
307,000 deaths[2]. The incidence and mortality of prostate cancer vary greatly in the 
world [2-4].  
 
The highest incidence of prostate cancer is observed in Oceania (111.6/100,000), 
followed by North America (97.2/100,000), Western Europe (94.9/100,000), Nordic 
Europe (85.0/100,000) and the Caribbean (79.8/100,000), while the incidence is much 
lower in Southeast Asia (11.2/100,000), North Africa (10.6/100,000), East Asia 
(10.5/100,000) and South-Central Asia (4/100,000) [2].  
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The highest prostate mortality is observed in the Caribbean (29.3/100,000), followed 
by South Africa and Central Africa (24.4/100,000, 24.2/100,000). As the incidence in 
Caribbean as high as 79.8/100,000, the ratio of mortality/incidence is 37%, much 
lower than that in South and Central Africa which is up to 90% [2, 4]. Although both 
the incidence and mortality in Southeast Asia, Central and South Asia are low, the 
ratio of mortality/incidence is as high as 64%[4]. Nevertheless, almost 70% of the 
newly diagnosed cases with prostate cancer in the world are in more developed 
regions such as North America, Oceania and Northern and Western Europe, the ratio 
of mortality/incidence in those area is only between 10-18% [2, 4] and the prostate 
cancer mortality rate has been decreasing over time[5, 6]. 
 
2. Risk factors of prostate cancer 
2.1 Race and ethnicity 
The incidence and mortality of prostate cancer vary greatly by geographic regions, 
strikingly, in the United States, the incidence and mortality of prostate cancer varies 
considerably by race and ethnicity [7, 8]. The prostate cancer incidence of the North 
America Africans is up to 208.7 per 100,000 and the mortality is up to 47.2 per 
100,000, while prostate cancer incidence in the Asian American, Native Hawaiians 
and Pacific Islander (AANHIP) is only 67.8/100000 which is almost one third of 
North America Africans, and one half of Non-Hispanic Whites (123/100000) [8]. The 
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incidence, the mortality, and the ratio of mortality to incidence is lowest in AANHIP 
rather than North America Africans and Non-Hispanic Whites [8]. Even though, 
disparities in the diagnosis, treatment, and survival of prostate cancer patients of 
different races are often attributed to socio-economic status and access to healthcare 
[9, 10], after adjusting for those effects, racial disparities in prostate cancer incidence 
and mortality rates in United State remain significant [11]. In the United States, a 
white person has a 16% lifetime risk of prostate cancer and a 2.5% chance of death 
from prostate cancer, while black people are 70% more likely to develop prostate 
cancer and 40% more likely to die [12]. 
 
2.2 PSA Screening 
In 1970 Wang and Valenzuela found that PSA was a highly sensitive marker of 
prostate cancer [13]. A longitudinal research project in Baltimore, revealed the 
relationship between serum PSA and prostate cancer [14]. In the late 1980s, PSA 
screening for prostate cancer diagnosis was adopted in the United States and 
subsequently in Europe, thus making the incidence of prostate cancer in the United 
States and Europe increase rapidly in the 1990s [15, 16]. However, due to the low 
specificity of PSA screening for high-grade, clinically significant disease, a 
considerable proportion of people were subjected to unnecessary prostate biopsy or 
diagnosed with indolent cancer resulting in overtreatment [17]. In Europe and the 
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United States, an estimated 23-42% of prostate cancer cases were over-diagnosed due 
to PSA screening (2002) [15]. Based on a large clinical study in the United States, 
USPSTF (US Preventive Services Task Force) recommended against PSA-based 
screening for prostate cancer for men of any age in 2012 [18], led to 18% relative 
decreasing in PSA screening rates for men aged over 50 between 2010 and 2013 [19]. 
However, among men greater than 75 years old recorded in the SEER database, the 
proportion of men presenting with metastatic disease increased from 2011 (7.8%) to 
2013 (12.0%). A study conducted by ERSPC found that for every 1,000 men screened 
for PSA, three patients were prevented from metastasis and one was prevented from 
cancer-specific death. Based on these observations, in 2017, the USPSTF revised its 
recommendations and suggested that the decision to perform a PSA test for men aged 
55 to 69 should be individualized by consulting their doctors [20]. Currently PSA 
screening rates in the United States and Europe are higher than that in other regions in 
the world. The latest data show that the screening rate for prostate cancer is 30.7% for 
American whites, 28.1% for American blacks and 25% for Asian Americans [21]. 
 
2.3Environmental factors 
The incidence of prostate cancer in East Asia (~10/100,000) is much lower than that 
in North American Asians (~67/100,000) indicating that environment may be 
important risk factors for is prostate cancer. With the growth of economic and the 
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adoption of Western lifestyles during the last decades, the incidence of prostate cancer 
in East Asia has increased significantly. Singapore, Japan and Taiwan have 
experienced a sharp increase in the incidence of prostate cancer, from a low level 
(~5/100,000) to 30/100,000, 30/100,000 and 40/100,000 respectively [22-24]. The 
incidence of prostate cancer in China increased from 5/100,000 (2000) to 10/100,000 
(2011) in ten years, and it is still growing. Current evidences have shown that obesity, 
high-fat diet, smoking and sunshine exposure may be risk factors for prostate cancer. 
Epidemiological studies on whether obesity increases the incidence of prostate cancer 
are very inconsistent, instead obesity increases the risk of prostate cancer progression 
[25, 26]. Animal model studies have shown that high-fat diets may induce prostate 
cancer progression through affecting growth factor signaling, lipid accumulation, 
inflammation and endocrine regulation. In addition, epidemiological evidence reveals 
that smoking is associated with the prognosis of prostate cancer[27], but its molecular 
mechanism is not well understood. There are studies indicating the short-day in high 
latitudes regions resulting high incidence of prostate cancer due to the insufficient 
sunshine exposure affecting vitamin D synthesis[28]. Nevertheless, low fat, 
vegetables, tomatoes, olive oil rich diets and exercise are protective for prostate 
cancer[29, 30].  
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2.4 Age 
Age has a great impact on prostate cancer incidence and mortality. The risk of 
prostate cancer begins to increase in men with age over 40 years old and increases 
sharply when over 50 years old [31]. Over two-thirds of prostate cancer cases are 
older than 65 years old [31, 32]. However, there is evidence that the older you are, the 
more likely you are to develop prostate cancer, and it has been hypothesized that if 
men do not die of other causes, prostate cancer is inevitable. Men under 35 have 
almost no risk of prostate cancer. Therefore, the lower incidence of prostate cancer in 
Africans than that in North America Africans is largely due to the lower life 
expectancy of African males. With the aging of the global population, we need to pay 
attention to the increasing burden of prostate cancer. 
 
2.5Infectious diseases 
Over the years, several studies have focused on the association between prostate 
cancer and viral infections including human papillomavirus (HPV), herpesviruses 
including cytomegalovirus (CMV), human herpes simplex virus type 2 (HSV2), 
human herpesvirus type 8, (HHV8) and Epstein-Barr virus (EBV), polyomavirus 
BKV and xenotropic murine leukemia virus-related virus[33]. But a systematic 
review in 2013 indicated that there was insufficient epidemiological evidence 
showing that a single infectious pathogen was associated with prostate cancer, which 
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may due to the limited sample sizes in the study, resulting in the impossibility to 
assess non-persistent infection, and on the other hand, prostate cancer may be 
associated by multiple infectious pathogens [34]. A recent analysis of 5000 prostate 
cancer patients and 6000 healthy people has found that HPV16 infection increased the 
risk of prostate cancer [35]. 
 
Due to the development of second-generation sequencing technology, the doctrine of 
sterility in urine has been overthrown [36, 37]. Urinary microbial homeostasis and 
pathogenic microorganisms may cause prostate cancer inflammation and thus 
promote tumorigenesis [38]. Several bacteria have been proven to cause bacterial 
inflammation of the prostate, including E.coli. and other species of Enterobacteriaceae 
[39]. Propionibacterium acnes has also been demonstrated to cause prostate cancer 
inflammation and promote tumorigenesis [40-43]. Evidence also shows that some 
sexually transmitted pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, 
or Trichomonas vaginalis are associated with prostate cancer [44-47]. Although it is 
hard to find a direct link between a single pathogen and the occurrence and 
development of prostate cancer, the relationship between various infections promoting 
inflammation of prostate cancer and the occurrence of prostate cancer has been 
gradually elucidated.  
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2.6 Family history  
The genetic risk of familial prostate cancer was first proposed in the 1950s. Johns et al. 
carried out statistical analysis of 13 case-control studies, showing that men with a 
family history of prostate cancer had a 2.5-fold increased risk for prostate cancer. In a 
subsequent large number of studies, it was confirmed that men with a family history 
of prostate cancer had an increased risk of prostate cancer, especially with the 
presence of early onset, a relative, or multiple cases in the family. In 2015, Albright et 
al. conducted a retrospective analysis of 443 men with complete family history and 
assessed the relative risk of PC [48]. All these men had complete ancestral genealogy 
data. It was found that the risk of prostate cancer was increased by 2.46 if there was 
only one male immediate relative suffered from prostate cancer, while the risk 
reached by 7.65 when at least four male immediate male relatives had been diagnosed 
with prostate cancer [48]. In cases who have at least one immediate relative was 
diagnosed with prostate cancer before the age of 50, the risk was 5.54 [48]. Current 
studies have shown that the risk of prostate cancer in men is also increased due to rare 
germline risk variants such as BRCA1/BRCA2 or DNA mismatch, and the presence 
of breast cancer, ovarian cancer, rectal cancer and Lynch syndrome in families [49]. It 
is generally believed that the history of prostate cancer, breast cancer, ovarian cancer, 
rectal cancer and Lynch syndrome in relatives within three generations increased the 
risk of prostate cancer in men [50]. 
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3. Heritability of prostate cancer 
Early genetic quantitative studies of identical and fraternal twins have showed that the 
heritability of prostate cancer is 42% - 58%, higher than that of any other malignant 
tumors [51-53]. Linkage analysis based on pedigree prostate cancer has identified 
several chromosomal loci related to prostate cancer genetics [54-58]. In 1996, Jeffery 
et al analyzed 66 families at high risk for prostate cancer and identified for the first 
time the susceptibility locus of chromosome 1q24-25, which was named Hereditary 
prostate cancer 1(HPC1) [54]. Through this method, several chromosomes with 
different prostate susceptibility loci were also identified, including chromosomes 2, 3, 
5, 6, 8, 10, 11, 13, 15, 17, 19, 20 and 22 [59, 60]. However, the chromosome regions 
identified by linkage analysis are too large to accurately identify the gene variant 
affecting the disease. Subsequent genome-wide association analysis (GWAS) and 
genome-wide exome sequencing further revealed susceptible variants in these regions, 
such as rs1006908 on chromosome 8q24 [61] and HOXB13 (G84E) on chromosome 
17q21.[62] 
 
3.1Loci with low penetration explain 19% of the hereditary of prostate cancer 
Similar to other complex genetic diseases, the inheritance of prostate cancer is 
affected by variants with high frequency but low penetration and low frequency but 
high penetration in the populations [63, 64]. Genome-wide association analysis can 
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identify SNPs with high frequency but low risk. In 2016, Gudmundsson et al. reported 
the first genome-wide association analysis of prostate cancer, which confirmed that 
chromosome 8q24 carries prostate cancer susceptibility genes [65]. With the increase 
of GWAS research sample size and the development of chip imputing, the efficacy of 
GWAS in identifying prostate cancer susceptible SNPs has been greatly optimized, 
and more susceptible sites have been identified [66-69]. Scyumacher et al. recently 
have identified 63 new prostate cancer sites by analyzing data from 140,000 men[70]. 
Todate, 167 prostate cancer susceptibility loci have been identified by genome-wide 
association analysis [70]. These loci with high frequency and low penetration explain 
about 19% of the familial risk of prostate cancer [70]. However, most of the GWAS 
associated sites are located in the non-coding regions, and the molecular mechanisms 
of their effects on prostate cancer is still unresolved [71]. One hypothesis is that 
variants in these loci are associated coding regions affect prostate cancer and the other 
one is that these loci affect the transcriptional regulation region of coding genes.  
 
3.2 Rare mutations on susceptible genes explain 15% of the hereditary of prostate 
cancer 
In recent years, the effect of variants with low frequency and high penetration on the 
heredity of prostate cancer has become clear, such as HOXB13, BRCA1/BRCA2, 
DNA mismatch and DNA damage repair pathway [72]. These variants account 
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forabout 5% of the family risk of prostate cancer [73, 74]. In the following we will 
introduce the mechanism and clinical manifestations of the population frequency of 
these gene mutations on prostate cancer.  
 
3.2.1 HOXB13 
In 2012, Ewing et al. scanned 200 genes in 17-21-17q22 of 96 patients in different 
prostate cancer family clusters, and found that 18 patients had HOXB13 G84E rare 
mutations [62]. Furthermore, they verified the mutation in 5083 unrelated prostate 
cancer cases of European descent and 1401 control subjects. The mutation rate was 
approximately twenty-fold higher in the prostate cancer cases (1.4% or 72 in 5083) 
than in the controls (0.07% or1 in 1401)[62]. Odds ratio of HOXB13 G84E for the 
development of prostate cancer was 5.1 among men with positive family history and 
early onset and 1.7 among men with no family history and late onset [62]. 
Subsequently, in a large international family risk study of prostate cancer, 5% of 
prostate cancer families had the HOXB13 G84E variant [75], with the highest variant 
frequency around 20% in Finland, followed by Sweden around 8.2% [76]. Evidence 
suggests that HOXB13 G84E appeared most prevalent in the Nordic population, with 
a moderate penetration rate [77]. Different HOXB13 mutations have also been 
detected in prostate cancer cases in other racial or ethnic groups, including in African 
[62] (G216C and R229G), Asians (G135E) [78] and Portuguese (A128D,F240L)[79], 
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but the frequency and impact of these variants on the risk of prostate cancer remains 
to be further confirmed. 
 
The HOXB13 gene encodes for a homeobox related transcription factor regulating a 
gene expression cascade which is critical for prostate development [80]. Other than 
that, HOXB13 protein has been shown to interact with Androgen Receptor signaling 




The relationship between BRCA1/BRCA2 and hereditary breast and ovarian cancer 
first revealed that BRCA1/BRCA2 mutations increase the risk of breast and ovarian 
cancer[83]. Subsequent studies have found that rare mutations in BRCA1/BRCA2 
also increase the risk of prostate cancer [84]. Many studies have shown that BRCA1 
mutations increase the risk of prostate cancer between 1.07 and 3.75 (odds ratio), 
while BRCA2 mutations increase the risk of prostate cancer more significantly 
between 4.65 and 8.6 (odds ratio). In a BCLC study involving 173 BRCA2 mutated 
families, the overall risk associated with prostate cancer in BRCA2 was 4.65, but in 
men who developed the disease before age 65, the risk rose to 7.33. In the study of 
prognostic analysis of patients with BRCA1/BRCA2 mutation, PSA-free survival and 
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overall five-year survival were significantly reduced in patients with BRCA2 
mutations. Strikingly, in a recent genomic study that including 150 metastatic 
castration resistance prostate cancers (mCRPC), 8% of the patients had germline 
variants of BRCA2.  BRCA1 and BRCA2 occur in about 0.87% and 5% of familial 
prostate cancers. Both BRCA1/BRCA2 mutations increases the risk of prostate cancer 
and BRCA2 mutations are associated with early onset of disease and prognosis. Due 
to relatively low numbers of cases carrying BRCA1/BRCA2 and the variability of 
specific mutations, the differences in mutation frequencies among different races is 
still unknown.  
 
BRCA1/BRCA2 is a tumor suppressor gene encoding proteins that repair damaged 
double-stranded DNA by high-fidelity replication using the undamaged sister 
chromatid as a template [85]. BRCA1 has a broad range of functions, including 
recruiting effector factors to double strand break sites, regulating end resection of 
DSBs, activating G1/S, S-phase, and G2/M checkpoints, and mediating 
non-homologous end joining, and single-stranded DNA annealing repair pathways [85, 
86]. The BRCA2 protein mainly recruits RAD51 and HR60 to DSB at the beginning 
of homologous recombination repair [87]. Deleterious mutations in BRAC1 and 
BRCA2 impair BRCA1/BRCA2 function and lead to instability of DNA, thus 
promoting carcinogenesis [88].  
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3.2.3 DNA mismatch repair genes 
DNA mismatch repair gene mutations was first identified as the causative gene of 
Lynch syndrome[89]. Researchers subsequently observed that Lynch syndrome 
patients had a higher incidence of cancer than that of the normal population, 
especially in rectal cancer. In 2004, Harakdsdottir et al. analyzed the SEER database 
and observed 11 out of 188 men with Lynch syndrome developed prostate cancer 
(relative risk 4.87). In 2009, Grindedal et at. confirmed that DNA MMR mutations 
increased the risk of prostate cancer by analyzing 106 men with DNA MMR 
mutations in the Norwegian Cancer Registry [90]. Ryan et al. assessed the relative 
risk of prostate cancer associated with DNA MMR mutation to be 3.36 [91]. Then 
Rosty et al. estimated the relative risk of prostate cancer associated with MSH2 (5.8), 
MLH1(1.1), and MSH6(1.3)respectively[92]. Inactivation of MMR proteins, result in 
a high rate of microsatellite instability (MSI) in their tumors [93, 94]. 
 
3.2.4 Other prostate cancer germline risk variants 
Other germline mutations are also associated with the risk of prostate cancer. In a 
study investigating germline risk mutations in metastatic prostate cancer, researchers 
found that 1.87% of metastatic tumors had CHEK2 germline mutations, 1.6% of 
ATM, 0.43% of PALB2 and 0.43% of RAD51D germline mutations [95]. A Polish 
study has found that NBN657del5 was present in 9% of pedigree prostate cancer 
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patients, and 2% of sporadic prostate cancer patients, while the mutation frequency in 
the control group was only 0.6%. In addition, in the recent TCGA pan-cancer study 
for screening germline risk variants, it suggested that germline variants on BRIP1, 
DKC1, EPCAM, GALNT3, MTAP, PMS2, POT1, RAD51C, RECQL, SEPRINA1, 
TSC1, TSC2, UROD and some other genes might also affect prostate cancer. 
 
4. Somatic Genomic alterations in prostate cancer 
Normal cells need to acquire multiple abilities to transform into tumor, including 
sustained growth signals, desensitization of growth inhibition signals, resistance to 
death, unlimited replication and proliferation, sustained angiogenesis, tissue 
infiltration and metastasis, avoidance of immune surveillance, and abnormal energy 
metabolism. Inflammation and genomic instability generate somatic mutations that 
expedites the acquisition of tumor promoting abilities. Before innovation of next 
generation sequencing technology, researchers identified a number of somatic 
mutation events in prostate cancer through fluorescent in-situ hybridization and 
comparative genomic hybridization, including loss of NKX3-1 [96, 97] and 
PTEN[98], amplification of MYC [99, 100] and AR [101]. Subsequent advances in 
gene expression profiling technologies led to the discovery of ETS family transcript 
factor over expression[102], and the discovery of recurrent TMPRSS22-ETS gene 
fusions in prostate cancer [103]. With the development of next generation sequencing 
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and bioinformatic analysis technologies comprehensive examination of prostate 
cancer genomes became an efficient tool for identification of cancer related mutations. 
In early prostate cancer genomic studies using next-generation sequencing, a large 
number of novel prostate cancer genomic alterations were identified [104-111]. 
However, due to the limitation of the sample sizes and early generation analytical 
methods, these studies failed to uncover the full spectrum of the complex 
heterogeneity of prostate cancer genomes. In 2015, the Cancer Genome Atlas
（TCGA）published a multi-omic genomic study which included 333 cases of primary 
prostate cancer [112]. Researchers found that 74% of prostate cancers could fall into 
seven molecular subtypes: 1) ERG fusion (46%), 2) ETV1 fusion (8%), 3) ETV4 
fusion (4%), 4) FL1 fusion (1%), 5) SPOP mutation (11%), 6) FOXA1 mutation (3%) 
and 7) IDH1 mutation (1%) [112]. Besides these reported mutations, TP53, PTEN, 
PIK3CA, RB1 and other gene alterations were also altered. In 2018, Joshua Armenia 
et al. combined genomic data from 1013 prostate cancer samples and identified that 
97 genes were significantly mutated in prostate cancer, 70 of which had not been 
reported before, such as the ubiquitin ligase CUL3 and the transcription factor SPEN 
[113]. In addition, they defined a new molecular prostate cancer subtype that has 
mutations on epigenetic related genes [113]. Other related studies have also revealed 
that local indolent prostate cancer had lower numbers of molecular mutations [114], 
instead metastatic prostate cancer had higher mutation burden rates [115]. 
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The unveiling of prostate cancer genome provided insights into prostate cancer 
biology and have enabled the identification of novel drug targets, diagnosis and risk 
stratification biomarkers for this disease. The molecular biology, diagnosis, risk 
stratification and therapeutic development of prostate cancer are presented in Chapter 
1.7，1.8and 1.9. 
 
5. Molecular evidence for racial disparities of prostate cancer 
In recent years, the molecular basis for racial disparities of prostate cancer has 
accumulated. Early GWAS studies revealed the 8q24 locus [58, 61, 116] and some 
other prostate cancer risk alleles [117, 118] were associated with African Americans. 
GWAS studies based on men from different populations, such as Latino [119], South 
Asian [120], Japanese [68, 121], and Chinese [122, 123] ancestries have further 
identified potential race-specific prostate cancer risk alleles. Later whole exome 
sequencing revealed that the rare mutation HOXB13 G84E occurred more frequently 
in the family prostate cancer of the Nordic populations [62, 76, 77, 124] and the rare 
variation in Tet2 is associated with clinically relevant prostate carcinoma in African 
Americans [125]. Most recently, prostate cancer genomic studies revealed ETS family 
fusions was the most common alteration in prostate cancer of Caucasian men at a 
frequency of ~50%, however, they are much lower in African American and Chinese 
[103, 126, 127]. Similar to ETS fusion, PTEN loss is more frequently found in 
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prostate cancer of Caucasian men than other ethnicities [128]. There are also other 
race-specific prostate cancer genomic alterations such as LSAMP loss [129], ERF 
loss-of-function mutations [130, 131] and CDC27-OAT [132] fusion in prostate 
cancer of African Americans. However, most of the genomic prostate cancer studies 
are focused on cohorts of European ancestry, leaving minority groups under 
represented [133]. Furthermore,in racial mixing, the ethnic contribution to riskis not 
fully understood. 
 
6. Oncogenesis and development of tumors 
The size of the prostate is slightly larger than the walnut. It is located at the bottom of 
the pelvic cavity, under the neck of the bladder, on the urethra; behind the pubis, 
before the rectum, and surrounds the junction of the bladder mouth and the urethra, 
with a seminal vesicle gland attached, and urethra and the vas deferens wrapped [134]. 
(Figure 1.1) The main function of the prostate is to secrete and store prostatic fluid. 
Prostatic fluid can be mixed with sperm to form semen which contains sperm and 
semen. About 10% to 30% of the semen is made from the prostate [134, 135]. The 
prostate also contains smooth muscle tissue, which helps ejaculation[135]. As prostate 
is located upstream of most male genital organs, including the vas deferens, 
epididymis and testis, the prostate is also considered the first line of defense for the 
male reproductive system against foreign antigens or pathogens from the bladder and 
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lower urethra [136]. The prostate is divided into transitional zone, central zone and 
peripheral zone. It consisted of 30 to 50 glands, with each one consisting of three 
basic types of cells, basal cells, luminal cells and neuroendocrine cells [137]. Most 
prostate cancers originate from luminal cells in the peripheral area of prostate cancer 
[138, 139]. The normal epidermal cells of the prostate develop into prostatic 
intraepithelial neoplasia, then local prostate cancer, then locally advanced prostate 
cancer, and eventually developed into metastatic prostate cancer [140-144]. With 
increasing age, inflammation prostatic atrophy is common [145, 146]. Inflammation 
atrophy has a larger impact area, especially in the peripheral areas with high incidence 
of prostate cancer [147]. Inflammation can be caused by infection and disruption of 
the epithelial barrier [33, 148]. Evidence suggests that inflammation-induced 
oxidative stress or reactive oxygen species (ROS) cause mutations in cell genes, 
leading to the transformation of normal cells to prostatic intraepithelial 
neoplasia[149-151]. In 2016, Mani, R.S. et.al found that inflammatory cytokine 
signals such as tumor necrosis factor (TNF) signals in epithelial cells result in DNA 
breaks which eventually lead to the fusion of TMPRSS2-ERG [152]. Other studies 
indicate bacterial infection leads to low expression of NKX3-1 in prostate epidermal 
cells [149]. Proliferative luminal epithelial cells of intermediate phenotype which 
abnormally express gene such as CDKN1B, GSTA1, COX2, MYC, PSA, AR, 
NKX3-1, MET, GSTP1 are enriched in prostatic proliferative inflammatory atrophy 
(PIA) [148, 153]. These studies suggested that inflammation can transform normal 
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cells to prostatic intraepithelial neoplasia. Besides, environmental toxins may cause 
DNA damage in normal epidermal cells of the prostate by triggering oxidative stress, 
which may lead to the carcinogenesis of epidermal cells, such asheterocyclic amines 
ingested from burnt diets through blood circulation to the prostate or by the urine 
reflux into the prostate also trigger oxidative stress [154-156].  
 
Figure1.1 The size of the prostate is slightly larger than the walnut. It is located at 
the bottom of the pelvic cavity, under the neck of the bladder, on the urethra; behind 
the pubis, before the rectum, and surrounds the junction of the bladder mouth and the 
urethra, with a seminal vesicle gland attached, and urethra and the vas deferens 
wrapped. 
 
Most prostate cancers are indolent, and only a small proportion of prostate cancers 
progress aggressively to metastatic tumors. Metastasis prostate cancer undergo 
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Epithelial to mesenchymal transition (EMT) to migrate to the adjacent lymph nodes 
and then to the lungs, liver or bone[157, 158]. Recent studies have suggested that 
circulating tumor cells [159, 160] and exosomes[161] may play an important role in 
tumor metastasis. Despite the efforts to reveal the mechanism of prostate cancer 
metastasis and to develop drugs for the treatment of metastatic prostate cancer, 
metastatic prostate cancer has not yet been cured so far. 
 
7. Prostate cancer diagnosis 
Current clinical diagnosis of prostate cancer is based on the framework established in 
the 1990s. It mainly includes three main indicators: serum PSA level, rectal digital 
examination and tissue biopsy. Patients with serum PSA greater than 4.0 or rectal 
finger positive need to be further confirmed by biopsy [162, 163].  
 
7.1 PSA screening 
In 1970s, Wang and Valenzuela found that PSA was a highly sensitive biomarker of 
prostate cancer[13]. Then, in a longitudinal study in Baltimore, the relationship 
between PSA in serum and prostate was further elucidated [14]. In the late 1990s, 
PSA was used to screen prostate cancer because of its high sensitivity to detect 
prostate cancer, replacing the previously used prostatic acid phosphatase (PAP)[164].  
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PSA is a glycoprotein and composed of 237 amino acids, secreted by prostate 
epithelial cells. Normally, PSA is not released into the blood, because of natural 
blood-epithelial barrier between the prostatic duct system and the peripheral 
circulation system, thus maintaining low concentration in the blood. The invading and 
migration of prostate cancer cells disrupt blood-epithelial barrier, resulting in 
increasing of PSA concentration in the blood. Unfortunately, blood PSA elevation is 
also observed in benign prostatic hyperplasia (BPH) and prostatitis [165]. High levels 
cannot distinguish cancer from inflammation especially in patients with serum PSA 
levels <10 ng/ml[166]. Instead of only serum PSA level, the ratio of free PSA to total 
PSA, PSA density, PSA ROS curve have been shown to increase the specificity of 
PSA, but with limited effect [167]. 
 
7.2 Biopsy 
The mode of prostate biopsies has evolved considerably over the years. Open or 
finger-guided transperineal biopsy with low accuracy was the standard method for 
biopsy sampling in the early 1920s. This method is very invasive, leading to high 
incidence of urinary incontinence and ED, and patients need to spend a long time in 
hospital to recover. The emergence of transrectal ultrasound (TRUS) guided prostate 
biopsy greatly improves the accuracy of biopsy and reduces the side effects of tissue 
biopsy [168]. In 1998, Levine and colleagues found that 12-core prostate biopsy 
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increased the detection rate of prostate cancer by 30% compared with 6 cores[169]. In 
2003, the guideline for prostate cancer biopsy was revised to 12 needle biopsy and 
enhanced sampling of the anterior and lateral regions [170]. Nevertheless, needle 
biopsy has a significant chance of missing the prostate cancer. Thirty percent of 
patients with negative biopsy were identified as prostate cancer positive by repeat 
biopsy [169, 170]. In addition, transrectal ultrasound guided prostate cancer puncture 
also increases the risk of bacterial infection of the prostate [164].  
 
7.3 Risk stratification 
The risk stratification system for prostate cancer was originally derived from the 
D'Amico classification [171] of low-risk, medium-risk, high-risk disease or the the 
Epstein criteria [172] for low-risk (clinically unimportant) cancer mainly based on 
Gleason score of tissue puncture biopsy, serum PSA level and clinical classification. 
However, the inaccuracy of the risk stratification resulted in a high proportion of 
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7.4 Development of prostate cancer diagnosis and risk stratification 
7.4.1 PSA derived 
Fortunately, the understanding of the biology of PSA secreting and maturation helps 
to the identification of greater specificity of PSA isoform biomarkers. In particular, 
the detection level of the [-2] pro-PSA ('p2PSA') in serum can improve the diagnostic 
specificity of prostate cancer compared with free PSA or total PSA. PSA is initially 
translated as inactive pre-pro PSA, which carries a 17-amino acid signal peptide. 
During the secretion of PSA, pre-pro PSA is cleaved to pro-PSA by removing the 
signal peptide. Mature PSA, pro-PSA still requires cleavage by human kallikrein 2 
(hK2) to remove the Pro precursor peptide of 7 amino acids at N terminal. In this step, 
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Figure1.2 Molecular forms of PSA. The arrows with dashed line mean the forms of 
PSA that go from the cell to the blood. PSA: prostate specific antigen, BPSA: benign 
PSA, iPSA: intact PSA, PSA-ACT: Alpha 1-antichymotrypsin-PSA, PSA-API: 
alpha1-trypsin inhibitor PSA, PSA-A2M: alpha 2macroglobulin, hK-2: human 
kallicrein 2, hk-4: human kallicrein 4. 
 
7.4.1.1PHI index 
In 2012, the Prostate health index (PHI)was approved by the U.S. Food and Drug 
Administration (FDA) for aiding doctors to determine whether a patient with PSA 
level 4-10ng/ml requires biopsy[174]. Prostate health index (PHI) is a diagnostic 
index for prostate cancer that combines serum total PSA, free PSA and [-2] pro-PSA 
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levels. It is calculated by the formula ([-2] pro-PSA/free PSA) * tPSA. Patients with 
high serum level of total PSA and [-2] pro-PSA, and with low level of free PSA have 
higher PHI scores and are more likely to suffer from prostate cancer [174]. Fossati 
and colleagues evaluated PHI index in a total of 2034 patients with PSA at 2.5-10 
ng/ml. In the ROC analysis, the AUC (Area under the curve) of PHI was 0.77, while 
the AUC of -2] pro-PSA was 0.76, % fPSA was 0.68, PSA was only 0.5[175].  
 
7.4.1.2 The 4Kscore 
The 4Kscore combines four prostate-specific biomarkers including total PSA, free 
PSA, intact PSA, and human kallikrein 2 [hK2] with clinical information to provide 
men with an accurate and personalized measure of their risk for aggressive prostate 
cancer [176, 177]. The 4Kscore Test was evaluated in multiple cohorts in Europe and 
subsequently validated in a US multicenter prospective study. Overall, the 4Kscore 
Test reduced prostate biopsy rates by 94% in men and there is evidence that the 
4Kscore can predict the likelihood of cancer spreading to other parts of the body in 
the next 20 years [178-180]. 
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7.4.2 Urine-derived biomarkers 
7.4.2.1 SelectMDx 
SelectMDx is a urine-based test based on prostate cancer genomic biomarkers 
HOXC6 and DLX1, which together have a 76% sensitivity (reliability) for detecting a 
prostate cancer that is aggressive enough (Gleason score of 7 or greater) to require 
treatment [181]. When additional risk factors (namely age, PSA, PSA density, family 
history and rectal examination) are added to the calculation, the accuracy of the test 
(negative predictive value) for excluding prostate cancer rises to 98%, with an 
expected total reduction of biopsies of 42%. So clearly there is great potential to avoid 
unnecessary prostate biopsies. A multi-centre scientific study made in 2016 and 
published in European Urology confirms the accuracy of the test[181]. while a 2018 
study in the Journal of Urology has concluded that „routine use of the SelectMDx 
urinary biomarker panel to guide biopsy decision making improved health outcomes 
and lowered costs in American men at risk for prostate cancer [182]. This strategy 




ExoDx Prostate(IntelliScore) is a clinically validated, non-digital rectal exam (DRE) 
urine-based liquid biopsy test that predicts the presence of high-grade (Gleason score 
Tiansheng Zeng 
Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 
University of Sassari 
29 
≥7) prostate cancer for men 50 years of age and older with a PSA 2 – 10 mg/mL 
presenting for an initial biopsy. A “rule out” test, ExoDx Prostate(IntelliScore) is 
designed to more accurately predict whether a patient presenting for an initial biopsy 
does not have high-grade prostate cancer and, thus, could potentially avoid an initial 
biopsy and, instead, they continue to be monitored [183]. ExoDx Prostateanalyzes the 
urine for three biomarkers on exoRNA that are expressed in men with high-grade 
prostate cancer. Using a proprietary algorithm that combines the relative weighted 
expression of the three-gene signature, the test assigns an individual risk score for 
patients ranging from 0 to 100. A score >15.6 is associated with an increased 
likelihood of high-grade prostate cancer on a subsequent biopsy [184]. 
 
Additional molecular markers of prostate cancer based on different urine are being 
studied, such as MI-Prostate Score based on urinary secretory microRNA, Progensa 
and Protarix based on urinary proteomics[185]. 
 
7.4.3 Genic Tests 
In 2017, the Philadelphia Consensus recommended that prostate cancer patients with a 
family history of HBOC and prostate cancer, as well as metastatic prostate cancer, 
need to undergo genetic screening for germline risk variants on genes 
includingBRCA1/2, HOXB13, and DNA mismatch repair genes [50]. Risk variants in 
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these genes not only increase the susceptibility to prostate cancer, but are also partly 
associated with the early onset and prognosis of prostate cancer or treatment selection 
[50].The risk genes and evidence discussed in the Philadelphia Consensus are shown 
in Table 3. 
 
8. Treatment of prostate cancer 
Alterative treatment selection for prostate cancer patients are mainly based on risk 
classification. In recent years, with the available of new targeted therapies and 
immunotherapy, genic testing become a supplemental option to guide the treatment 
selection [49]. 
 
8.1 Active monitoring for very-low risk prostate cancer 
Recent studies have shown that very low-risk prostate cancer tends to remain indolent. 
The probability of their progression to metastatic prostate cancer or cause death is 
very low. To avoid side effects caused by treatment, in 2017, the American Urological 
Association announced that it is best for men who are diagnosed with very low-risk 
prostate cancer to actively monitor disease progression rather than receive treatment.  
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8.2 Activemonitoringfor low risk prostate cancer 
Men who are diagnosed with low-risk prostate cancer should also be given priority in 
actively monitoring disease progression as well.Active monitoring is usually 
performed on patients with low-risk prostate cancer undergoing serum PSA 
monitoring, repeated prostate biopsy and MRI. Datahave shown that patients with 
low-risk prostate cancer under active monitoring have a probability of dying from 
prostate cancer less than 1% within10 years.[186] 
 
8.3 Treatment for patients with low risk cancer 
Because some lesions affect the daily life of patients, for patients with low-risk local 
prostate cancer, radical prostatectomy, external beam radiotherapy and brachytherapy 
are often used clinically. Othertreatments, such as cryotherapy, high-intensity focal 
ultrasound and photodynamic therapy, are also used [186]. 
 
8.4 Treatment for locally advanced prostate cancer 
For patients with locally advanced or high-risk prostate cancer, recent studies have 
shown that radical prostatectomy plus ADT or radiotherapy plus ADT can 
significantly reduce the 10-year mortality risk compared with ADT alone. However, 
10% to 20% of patients havebiochemical recurrence with elevated serum PSA in 2~3 
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years after ADT treatment and develop into castration resistant prostate cancer (CRPC) 
followed by metastasis to bone, lung and other sites (mCRPC). The median survival 




8.5.1 Second Generation Androgen Receptor Antagonists 
Although many patients develop resistance after 2~3 years of ADT treatment, 
mCRPC is AR signaling dependant. In 2012, the second generation AR antagonist 
Enzalutamide [188]was approved by FDA in the United States for the treatment of 
mCRPC. In clinical trials, Enzalutamide significantly improved overall survival (OS) 
and progression-free survival (PFS) in patients with prostate cancer after 
chemotherapy.  
 
In 2012, Abiraterone, an inhibitor of CYP17A1, was also approved by FDA to treat 
mCRPC. CPY17A1 is an important enzyme in androgen synthesis pathway. It can 
effectively inhibit androgen synthesis by inhibiting CYP17A1. Clinical data showed 
that abiraterone combined with low-dose synthetic glucocorticoids effectively 
prolonged progression-free survival of the patients (5.6 vs 3.6 months, P < 
0.001)[189]. 
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8.5.2 PAPR inhibitor 
A recently completed phaseclinical trial showed that PARP inhibitor 
(Lynparza/a/olaparib) significantly improved disease-free progression survival in 
mCRPC patients with BRCA1/2, and ATM mutations, compared with Enzaluramide 
and Abiraterone [190]. 
 
8.5.3 Siupleucel-T 
Sipuleucel-T is an autologous dendritic cell vaccine targeting Prostatic acid 
phosphatase (PAP). In 2010, the FDA approved sipuleucel-T as the first and only 
immunotherapy for mCRPC[191]. In clinical trials, the 36-month survival rate in the 
Sipuleucel-T group was 31.7% while 23.0% in the placebo group[192]. 
 
8.5.4 Chemotherapy 
In 2004, TAX327 reported that chemotherapy drug docetaxel improves outcomes in 
mCRPC. Tannock et al. demonstrated in a randomized trial of 1,000 men with 
mCRPC that docetaxel chemotherapy improved patient survival by nearly 3 months, 
with 45% of patients having a 50% reduction in PSA [193]. In 2015, the taxanes 
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represented by docetaxel in combination with prednisone have been used as first-line 
treatments for mCRPC patients [194]. 
 
8.5.5 Ra223mCRPC 
Ra223 was approved by FAD in 2013 for the treatment of mCRPC with bone 
metastases. Clinical trial shows that Ra223 can increase the median survival time of 
mCRPC patients with bone metastases by 4.5 months[195]. 
 
9. Translate genetics to biology and therapeutics 
The treatment of mCRPC has made great progress, but due to the heterogeneity of 
tumors and drug resistance during treatment, the fact is that mCRPC still cannot be 
cured. In recent years, a large number of new prostate cancer driver genes (potential 
targets) have been identified in prostate cancer genomic studies, and the 
breakthroughs in immune cell therapy and immune checkpoint therapy in other 
tumors have encouraged researchers to move forward. 
 
In 1941, Charles Huggins first reported the beneficial effect of androgen ablation 
on metastatic prostate cancer. This discovery greatly inspired researchers to develop 
androgen deprivation therapy (ADT) for prostate cancer. ADT therapy is still a very 
important therapy for prostate cancer. Although 10% to 20% of patients have 
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biochemical recurrence with elevated serum PSA in 2~3 years after ADT treatment 
and progresses to CRPC which is associated with a poor prognosis. 
 
Recent advances in prostate cancer genetics and genomics have provided considerable 
insights into prostate cancer biology and have identified a considerable number of 
cancer drivers which can be exploited as novel drug targets. 
 
By 2018, More than 97 somatic drivers, 20 susceptibility genes, 167 germline risk 
alleles, in prostate cancer have been identified. To unveil the targetability of them, 
Wedge et al. conducted computational chemogenomic analysis of prostate cancer 
drivers and identified 11 targets of approved drugs, 7 targets of investigational drugs, 
and 62 targets with compounds that may be active and should be considered 
candidates for future clinical trials[196]. 
 
The following summarizes the most promising targets for prostate cancer discovery 
and highlight key signaling pathways as potential sources of targets including 
Androgen receptor signaling, the PIK3-AKT signaling, the WNT signaling, the DNA 
repair defects, the MAPK signaling. 
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9.1 AR signaling 
9.1.1 GnRH 
Gonadotropin-Releasing Hormone (GnRH), also known as Luteinising-hormone 
releasing hormone (LHRH), plays a crucial role in anti-androgen therapy [197]. 
Natural GnRH receptor agonists are secreted by hypothalamus and activate the 
receptors in the pituitary, increasing the release of LH (luteinizing hormone[198]) and 
ACTH (adreno-cortico-tropic-hormone) from the pituitary[199]. LH and ACTH 
promote corresponding target organs respectively to increase androgen secretion. In 
1971, the chemical structure of GnRH in pigs was obtained [200]. Then a series of 
active analogue agonists were developed.  
 
The persistent activation of GnRH receptor by GnRH analogue agonists depletes the 
pituitary of LH and ACTH, and the ultimate result is that androgen levels continue to 
drop to a very low level. In a phase III trial for patients with locally advanced prostate 
cancer, the 5-year clinical disease-free survival rate was 40% (95% CI 32% - 48%) in 
the radiotherapy group compared to 74% (95% CI 67% - 81%, P < 0.001) in 
theGnRH analogues and radiotherapy combined therapy group [201]. Therefore, 
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The persistent activation of GnRH receptor in the early stage causes a temporary rise 
in testosterone levels and promotes the progression of the disease. To resolve the 
adverse effects of GnRH receptor agonists, the development of GnRH receptor 
antagonists has been investigated. Antagonists inactivate the GnRH receptor by 
competitive binding with receptors. In 1997, Abarelix, a potent GnRH receptor 
antagonist, was successfully developed. Subsequently, several GnRH receptor 





In 1990, the first generation of non-steroidal androgen receptor antagonists, flutamide 
[204] was approved and rapidly used as an important drug in the treatment of 
advanced prostate cancer, followed by Nelutamide and bicalutamide [205]. Flutamide 
must be absorbed in the gastrointestinal tract and metabolized in the liver to be 
activated leading to hepatotoxicity [206]. In addition， Drug resistance to the first 
generation non-steroidal androgen receptor antagonists caused by 
T877A[207],W741C[208] and F876L[209] mutations in the ligand binding domain of 
AR is usually observed within 1 year after first administration. In 2012, the 
second-generationnon-steroidal androgen receptor antagonist Enzalutamide was 
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approved by FDA. Enzalutamide is able to overcome the resistance caused by W741C 
mutation and has 8-fold greater affinity for AR than the first generation of 
non-steroidal androgen receptor antagonist[188]. Apalutamide with the same 
mother-ring chemical structure as Enzalutamide has been approved to treat CRPC in 
2018 [210]. There was no obvious hepatotoxicity for the two drugs but seizures or 
rash and hypothyroidism are common side effects [188, 211]. Drug resistance is 
usually observed about 2-3 year later after administration because of AR F867L 
mutations, over-expression of AR-V7, AR co-activator, or activation of 
glucocorticoid receptor signaling [212].  
 
A new non-steroidal androgen receptor antagonist,Darolutamide which is able to 
overcome the resistance caused by AR mutations including F867L, W741L and 
T877A has shown stronger antitumor activity and stronger AR affinity than 
Enzalutamide [213, 214]. It should be approved by the FDA to treat the mCRPC in 
the near future. 
 
9.1.2.2 AR-nonLBD 
Androgen receptor (AR) is a steroid hormone receptor in the nucleus, which contains 
a central DNA binding domain (DBD), ligand binding domain (LBD), and hinge 
domain and N-terminal domain(NTD). Mutations in AR-LDB domains and the 
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expression of AR-V7 without AR-LDB domain can lead to resistance to 
Enzalutamide and other second generation of AR antagonists [212, 215]. To 
overcome the resistance, drugs that bind AR non-LBD domain become a new strategy. 
Niclosamide has long been used as an anthelmintic, but it have been found that it can 
promote the degradation of AR-V7and effectively inhibit the growth of tumors [216]. 
Other strategies for degradation of AR have been investigated as well. The clinical 
trial of AR-110, an effective AR degrading agent developed by PROTAC (Proteolysis 
Targeting Chimera) technology is ongoing. 
 
9.1.3 AR-binding protein 
HSP90 is a chaperone protein that binds AR and maintains full-length AR in a 
high-affinity ligand-binding conformation[217]. Inhibition of HSP90 results in 
abnormal AR signaling [218, 219]. Both in vitro and in vivo models, HSP90 
inhibitors also result in depletion of AR-V7[220]. However, phase I and phase II 
studies of HSP90 inhibitors have been generally disappointing because of poor patient 
tolerability and modest antitumor activity [221, 222]. Nonetheless, in the clinical 
studies of patients with advanced prostate cancer, inhibitor of HDAC which acetylates 
and activates HSP90 by acetylation, showed anti-tumor activity[223]. 
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FOXO1 binds to AR-NTD domain and inhibits AR transcriptional activity[224]. 
However, PTEN deletion in prostate cancer results in AKT activation which 
phosphorylates the FOXO1 resulting in its nuclear exclusion [225, 226]. In a phase II 
clinical study, ATK inhibitor Ipatasertib combined with abiraterone showed better 
anti-tumor activity than abiraterone alone, especially in prostate cancer patients with 
PTEN deletion [227].  
 
9.1.4 CYP17A1 
CYP17 are key enzymes in the synthesis of testosterone. Ketoconazole, an antifungal 
drug, has been found to broadly inhibit CYP17 enzymes and has been widely used in 
the treatment of prostate cancer before [228]. Due to its hepatotoxicity, ketoconazole 
has been limited in the clinical treatment of prostate cancer[228]. Nonetheless, a 
CYP17A1 inhibitor, abiraterone[189]combined with low-dose glucocorticoid 
effectively prolonged the progression-free survival (5.6 vs 3.6 months, P < 0.001) of 
mCRPC. Abiraterone, was successfully approved by FDA to treat mCRPC in 2012. 
 
9.1.5 5alpha reductase 
5 alpha reductase can reduce testosterone to highy active dihydrotestosterone [229], 
so 5alpha reductase inhibitors also play a role in the treatment of prostate cancer[230]. 
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For example, dutasteride combined with abiraterone can effectively improve the 





Figure 1.3 The cellular biology of prostate cancer. The complex underlying cellular 
biology and signaling cascades associated with prostate cancer are illustrated.  
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9.2 DNA repair Defects 
Both germline and somatic genomic aberrations of DNA repair genes have been 
reported in prostate cancer. Causative germline mutations in DNA defect repair genes 
occur in 5% of hereditary prostate cancer carries[64], and strikingly, in 8-15% of 
mCRPC. Somatic mutations of DNA repair genes occur in almost 23% of 
mCRPC[111]. The most commonly aberrant genes are BRCA1/2 and ATM. 
 
In 2005, studies showed that PARP inhibition could lead to death of BRCA1/2 
deficient tumor cells [232]. Several studies over the past decade have demonstrated 
the utility of PAPR inhibitors in different types of tumors[233-235]. The PARP 
inhibitor olaparib has been approved by the FDA for the treatment of women with 
advanced ovarian cancer. While for mCRPC, recent clinical trials showed that PARP 
inhibitor (Lynparza/a/olaparib) significantly improved disease-free progression 
survival in patients with BRCA1/2, ATM mutations, compared with Enzaluramide 
and Arbitrone[190]. 
 
PARP (Poly ADP-ribose polymerase) detect and initiate an immediate cellular 
response to single-strand DNA breaks. Inhibition of PARP in the DNA repair 
deficient tumor results in synthetic lethality of the tumor cells [232, 236]. There are 
also studies suggesting that PARP inhibitors may have broader anti-tumor activity as 
PARP interacting with ETS and AR [237, 238]. 
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In addition, DNA mismatch genes aberrations such as MSH6, MSH2, PSM2 occur in 
prostate cancer and potentially other defects in DNA repair [90, 239, 240]. These 
aberrations impair DNA mismatch repair, lead to an increase in mutation burden of 
tumors. There is also evidence showing microsatellite instability in tumors associated 
with DNA mismatch mutation, therefore, MMR defects can sensitize cancer to 
immunotherapy (Anti-PD-1, anti-CTLA4 therapeutics)[241, 242]. So far, patient 
selection approaches in CRPC for immune-checkpoint targeting have yet to be 
pursued. 
 
9.3 PIK3-AKT pathway 
PIK3-AKT signaling pathway is altered in 19% of local prostate cancer and 30% 
ofmCRPC. PTEN deletion is the most common aberration affecting 12% of local 
prostate cancers and 25% of mCRPC[112, 243]. Animal model experiments 
confirmed that the deletion of PTEN resulted in the formation of precursor prostate 
cancer lesions [244] and promoted disease progression when such features are 
combined with abnormalities in ERG, TPP53 [245, 246]. 
 
In tumors lacking PTEN, PI3KCA activity is suppressed while PI3KCB signaling is 
active. But in clinical studies with PI3KCB inhibitors, whether it was used alone or in 
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combination with docetaxel, the overall 1-year survival rate have not been shown to 
improve[247]. The reason for this may be that the inhibition of PI3KCB only results 
in the inhibition of AKT-mechanistic target of mTOR signaling which relives the 
feedback inhibition onupstream substrates and thus causes activation of PI3KCA and 
a rebound in downstream signaling[248]. However, Dactolisib, an inhibitor of 
multiple targets including PI3K and mTOR also have not shown any therapeutic 
advantage [249].  
 
Inconsistent with PI3K and mTOR inhibitors, ATK inhibitor Ipatasertib combined 
with abiraterone showed better anti-tumor activity than abiraterone alone, especially 
in prostate cancer patients with PTEN deletion [227]. Studies have shown that the 
anti-tumor activity of ATK inhibitors benefit from PTEN-AKT-FOXO1 axis instead 
of AKT-mTOR signaling [225]. 
 
Recent studies also indicate that PTEN loss induces cellular senescence and 
myeloid-derived suppressor cell infiltration can block this senescence [245, 250, 251]. 
In the PTEN-null mouse model, infiltration of CD11b+, glucocorticoid receptor 
1-positive myeloid cells protect a population of proliferating tumor cells from 
senescence. These myeloid-derived suppressor cells appear to infiltrate the prostate 
along a chemokine-chemokine receptor (CXCR2), and release IL-1 receptor 
antagonist, which inhibits senescence and drives proliferation. These findings 
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suggested that, targeting innate immunity may be a new therapeutic approach for 
PTEN-loss prostate cancer [252, 253].   
 
9.4 ETS gene rearrangements 
The transcription factors of ETS family such as ERG, ETV1, ETV4, FLI1 have 
important oncogenic roles in many prostate cancers. ETS rearrangements were found 
in about 40-60% prostate cancer patients of European ancestry. The most common 
rearrangement are ERG (46%), followed by ETV1 ( 8%), ETV4 (4% )and 
FL1( 1%)[254].  
 
ERG usually fuses with TMPRSS2 which is regulated by an androgen -regulated 
promoter element[103]. TMPRSS2-ERG fusion leads to ERG overexpression, 
resulting in AR expression and tumor cell proliferation[255]. Overexpression of ETS 
induces the formation of prostatic intraepithelial neoplasia(PIN) in a genetically 
engineered mouse model[153]. When combined with increased AR signaling or 
PTEN loss，Overexpression of ETS leads the progression of tumors[153]. Therefore, 
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Transcription factors are generally considered as undruggable targets. However, new 
strategies of modulating the activity of transcription factors have shown promise, 
including disrupting the interaction between transcription factors and other proteins 
andthe interaction between proteins and DNA, or restricting the binding of 
transcription factors by epigenetic modification of chromosome[256]. Currently, such 
as dithiophene diamidine compounds and DB1255 which inhibit ERG-DNA 
interactionsare under development[257]. In addition, clinical trials using optimized  
liposome-encapsulated siRNA to silence ERG expression in prostate cancer is 
ongoing[258].Another potential therapeutic strategy is to target the downstream 
effectors of TMPRSS2-ERG. Evidence shows that PLA2G7 is up-regulated in 
ERG-positive cancer and PLA2G7 silencing by siRNA sensitized 
ERG-rearrangement-positive VCaP cells to oxidative stress, reducing cell viability 
[259, 260].  
 
In addition to ERG rearrangement, YK-4-279, a small molecule drug targeting the 
FLI1 rearrangement, has reached phase I clinical trials for Ewing sarcoma treatment 
[261]. YK-4-279 inhibits the binding of EWS-FL1 to RNA helicase and induces 
apoptosis of cancer cells.YK-4-279 also shows the ability to inhibit ERG and ETV1 
rearrangements in vitro [262]. 
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9.5 TP53 
As the most common aberration, TP53 mutations are carried in 41% of pan-cancers, 
especially in HGSOC (high-grade serous ovarian cancer) (98%), esophageal 
adenocarcinoma (89%) and small cell lung cancer (85%). Almost 15% of 
mCRPCcarry TP53 mutation[263].  
 
TP53 is a tumor suppression gene, encodes the p53 protein which maintain a low 
level by MDM2 regulated post-translational ubiquitin degradation in normal cells. 
When DNA is damaged, cellular stress induces phosphorylation of MDM2 and 
acetylation of p53, leading to accumulation and activation of p53. Activated p53 
proteins stopproliferating cells in G1/S phase to repair the DNA damage[264]. 
Oncogenic stress triggers a DNA damage response involving p53, which constitutes a 
major barrier against tumor development. However, recent studies have shown that 
this effect of p53 is dispensable in tumors, and that p53 maintaining the homeostasis 
of cellular metabolism and redox balance in cell is even more important[265]. 
Moreover, many mutant p53 proteins have acquired gain-of-function (GOF) activities 
[266-268], which enable them to, for example, inactivate other p53 family members, 
in particular the tumor proteins p63 and p73 [269].(Figure 1.4) 
 
In contrast to aberrations in tumor suppressor genes such as RB1, adenomatous 
polyposis coli (APC) and PTEN, most TP53 mutations are missense mutations [113]. 
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Therefore, a drug development strategy for p53 is to use small molecules that promote 
proper folding and/or reactivation of common missense-mutant p53 proteins. Several 
of these compounds show significant anti-tumor activity in vitro and in vivo models.  
Clinical trials of two of the mutant-p53-targeting compounds are ongoing. APR-246 is 
being tested in phase II trial s[270], while the molecule COTI-2 is being studied in a 
phase I trial [271]. Although the current clinical trials do not include the treatment of 
prostate cancer, the efficacy of these drugs in the treatment of prostate cancer with 




Figure1.4Mutant p53 proteins have acquired gain-of-function (GOF) activities, 
inactivate other p53 family members, in particular the tumor proteins p63 and 
inhibit the transcription activities of p63. 
 
9.6 WNT signaling 
Aberrations that result in WNT pathway activation, such as loss of function of APC 
(adenomatous polyposis coli protein), mutations in genes encoding beta-catenin and 
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mutations in RNF43 have been reported in 15% of the mCRPC[254]. RNA-seq 
revealed that WNT beta-catenin signaling is a functionally important pathway for 
androgen-independent prostate cancer progression [272, 273]. Therefore, targeting 
WNT signaling in the subset of the mCRPC with activation of this pathway is 
promising. There are multiple compounds engaged in clinical trials for solid tumors 
[274]. As well the efficacy of these drugs to treat mCRPC with WNT 
pathwayaberrations should also be investigated in the future. 
 
9.7 The RAS-RAF-MEK signaling 
Arguably less common in prostate cancer, but nevertheless still clinically relevant and 
potentially targetable, is oncogenic activation of RAS-RAF-MEK signaling [275, 
276]. Such activation includes uncommon (1-2%) recurrent BRAF and RAF1 
rearrangements as well as rare mutations of these genes [277] and other aberrations of 
genes activating this pathway, including HRAS, SPRED, SPROUTY, FGF, and 
FGFR[112, 113]. 
 
As ETS proteins are downstream effectors of RAS-RAF-MEK-extracellular 
signal-regulated kinase(ERK) signaling, resistance to AR blockade in 
ETS-rearrangedprostate cancer has been postulated to involve RAS-RAF-MEK 
signaling[278]. Activation of the MAPK pathway could also activate ETS signaling in 
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some ETS-rearrangement-negative tumors[279]. Studies of RAS-RAF-MEK 
inhibitors in CRPC are now needed to understand which subtypes of these cancers are 
driven by MEK, to further elucidate the importance of this pathway in CRPC. 
 
10. Objectives 
The incidence of prostate cancer in Europe also varies greatly in different regions, 
with a high incidence in Western and Northern Europe and a low incidence in 
Southern Europe. Sardinia is an island in the middle of the Mediterranean Sea, north 
to the European mainland and south to North Africa[2]. The incidence of prostate 
cancer in Sardinia is lower than in mainland Europe. Most recently Sardinian prostate 
cancer incidence is about 44 per 100,00, while Southern Europe is about 58 per 
100,00 and Western and North Europe is up close to 100 per 100,00 [280, 281]. 
What‟s more, Chiang et al. demonstrated that Sardinia is a genetically isolated 
Mediterranean population and a purported refuge population of Neolithic ancestry. 
The evolutionary divergence from the European mainland population appeared to 
143.3±1.3 generations (~4,300 years ago) which was much earlier than the divergence 
between Southern and Northern Europe [282]. Therefore, the genetic disparities may 
possibly explain of the disparities of prostate cancer incidence between Sardinian and 
other ethnic or populations.  
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Race and ethnicity are risk factors for prostate cancer. The effects of race and 
ethnicity on prostate cancer are not only reflected in different incidence but also in 
different frequencies of ETS family fusion in different groups. ETS family fusions is 
the most common alteration in prostate cancer of Caucasian men at a frequency of 
~50%, however, they are lower in African Americans and Chinese at 20-30% and 
10-20% in respectively. So far, most of the genomic prostate cancer studies are 
focused on cohorts of European ancestry, leaving minority groups underrepresented. 
Furthermore, in racial mixing, the ethnic contribution to risk is unclear. These 
problems pose a serious challenge to a compressive understanding of genetic risk, 
diagnosis and treatment of prostate cancer patients [133]. 
 
My aim is to determine the genomic landscape of prostate cancer of Sardinian 
population. This will better define prostate cancer risk management and treatment. It 
will also provide a better understanding of the effects of genetic factors on prostate 
cancer in the genetically unique Sardinian population. 
 
My Specific Objectives ARE: 
1.Characterize the somatic mutation and indels in prostate cancer of Sardinia 
2.Characterize the Copy number variation in prostate cancer of Sardinia 
3.Characterize the fusion events in prostate cancer of Sardinia 
4.Characterize the germline risk in prostate cancer of Sardinia 
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Notes: To unveil the ethnic disparities of molecular basis of prostate cancer, we will 
also conduct a genomic study in Chinese prostate cancer cohort which is briefly 
summarized in the discussion chapter.“A brief summary of a genomic study in 
Chinese prostate cancer cohort”. 
 
ChapterⅡ. Material and methods 
1. Patients and Samples 
This research was approved by the Ethical Committee of the Sassari AOU. Our study 
includes 30 patient tumor resections before ADT treatment. FFPE sections were 
stained with hematoxylin and eosin and reviewed by experienced pathologists to 
determine the Gleason score and mark a boundary betweentumor lesions and 
corresponding tumor adjacent tissues. Paraffin blocks were divided into two sections 
based on histological findings. DNA extraction was conducted separately on each 
divided paraffin block.  
This research on Chinese prostate cohort was approved by the Ethical Committee of 
the Shantou University Medical College. 
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2. DNA extraction from FFPET tissue 
QIAGEN Gene-Read DNA FFPE Kit enables purification of high-quality genomic 
DNA and removes artificial C>T mutations and was utilized to extract DNA from the 
formalin-fixed paraffin-embedded tissue (FFPET). All the procedures followed the 
manufacturer protocols. The concentration and quality of DNA were determined by 
Qubit3.0 and Agilent 2100. The qualified DNA with a fragment size more than 800 
bp and the total amount of 100 ng was used for library preparation.  
 
3. Whole Exome Sequencing Library Preparation 
100~200ng DNA per sample was used for library construction using the KAPA 
Hyper-Plus Kit. Enzymatic fragmentation was performed according to the 
manufacturer instructions. Fragments with a size of 180-220bp before adapter ligation 
were selected for capture using the Roche Seq-Cap EZ Med-Exome system resulting 
in a total capture of 67Mb. Libraries were analyzed for size distribution by Agilent 
2100 Bioanalyzer and quantified by real-time PCR. The qualified libraries were 
sequenced by the Illumina X-ten platform with 8 samples per lane.  
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4. Sequence data Quality control. 
The original fluorescence image files obtained from X-ten platform were transformed 
to short reads (Raw data) by base calling and the short reads were saved in FASTQ 
format, containing sequence information and corresponding sequencing quality 
information. Reads were filtered as follows:1) Discard paired reads if either read 
contained adapter contamination (>10 nucleotides aligned to the adapter, allowing ≤ 
10% mismatches); 2) Discard paired reads if more than 10% of bases are uncertain in 
either read; 3) Discard paired reads if the proportion of low quality (Phred quality <5) 
bases is over 50% in either read. All downstream bioinformatics analyses were based 
on the high-quality cleaned data. 
 
5. Read mapping and processing. 
Sequencing data was mapped to the reference human genome (UCSC hg19) using the 
Burrows-Wheeler Aligner (BWA) software to obtain the original mapping results in 
BAM format [283]. Then, SAMtools, Picard, and GATK tool kits were used to sort 
BAM files and duplicate marking, local realignment, and base quality recalibration to 
generate final BAM files for somatic and germline SNVs and indels calling[284, 285]. 
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6. Somatic SNP and INDEL calling and annotation 
Somatic SNVs were identified by GATK muTect1. Somatic INDels were identified 
by Pindel based on paired bam files that were generated from paired tumor and tumor 
adjacent normal tissues [286]. The minimal depth for high confidence SNVs was set 
as 10, while a depth of 20 was set for INDELs. Based on high sensitivity of the Pindel 
algorithm and the possible damage of DNA due to historical FFPETs (>5 years), 
single nucleotide deletions were removed from final results. Annotation of the 
somatic SNVs and INDELs was performed using Oncotator[287]. The annotated 
MAF files were used for downstream analysis. 
 
7. Identification of mutation drivers 
To obtain putative driver mutations in our Sardinian prostate cancer cohort,SNPs and 
indels were mapped to OncoKB database. [288]. OncoDriveCluster was used to 
predict significantly mutated genes in our Sardinia prostate cancer cohort [289] that 
may represent novel driver mutations. Novel mutations as well as the identified 
OncoKBc identified genes were mapped to cancerhotspots and the 3Dhotspots 
database, and then analyzed with MutationAssessor, SIFT, Polyphen2, and FATHMM 
[290-292]. Candidate driver mutations were defined as, listed in the Cancer hot spots, 
or 3D hot spots, or annotated as damage mutations by at least three of the four 
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methods, MutationAssessor, SIFT, Polyphen2, and FATHMM. Protein 3D structures 
were downloaded from the PDB database and virtualized by PYMOL [293]. 
 
8. Germline SNVs and INDELs calling and candidate germline risk 
identification 
GATK-HaplotypeCaller was utilized to call germline SNVs and INDELs from tumor 
adjacent tissues [294]. Mutations with QUAL>200 were identified and annotated by 
ANNOVAR. Mutations with a MAF>0.01 in either 1000 Genomes or Exome 
Sequencing Project (ESP) databases were removed. Candidate germline risk 
mutations were then assessed as possible damage mutations using four methods, 
MutationAssessor, SIFT, Polyphen2, and FATHMM. Here we considered only 
mutations as damaging if identified by all four methods. Truncating mutations in 
tumor suppressor genes were considered as candidate germline risk mutations as well. 
Mutations identified in more than three samples or annotated by the 
FamilialCancerDatabase were considered as high confidence mutations [295]. 
 
9. Fusion calling, filtering, ORF prediction and visualization 
Fusion event calling from raw read files of tumor adjacent tissues and tumor lesions 
was performed using FusionMap which is designed to detect and align fusion 
junction-spanning reads to the genome directly [296]. Fusions were filtered out if 1) 
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seed reads were <=3 or were listed in the in-family analysis or found in a paralog 
gene list, 2) fusions associated with uncharacterized genes, immunoglobin genes, 
mitochondrial genes or repeat regions, and 3) fusions that were reported in normal 
samples. High confidence fusions were input into FusionHub to search for reported 
fusions and predict the fusion effects. GO, KEGG and Reactome pathway enrichment 
analysis of fusion genes were performed by metascape[297]. 
 
10. Copy number variation calling, filtering and driver copy number variation 
identification 
Control-FREEC was used to detect CNV with paired pileup files that were generated 
from unsorted bam files [298]. High confidence somatic CNVs were identified with a 
p-values less than 0.01 for both Wilcoxon and the Kolmogorov-Smirnov tests. They 
were next annotated by ANNOVAR [299]. Intergenicregions were then removed. 
Copy number variation reoccurring analysis was performed using GISTIC 2.0 [300]. 
 
Sardinian prostate cancer driver copy number variations already present in 
OncoKBannotatedalterations were classified as Putative copy number variations. 
Classification of Sardinian “candidate driver copy number variations” was based on 
curation in OncoKB onco-gene (amplification) or in OncoKB tumor suppressor gene 
(loss). 
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11. Integrative analysis of SNP, INDEL, fusion and copy number variation 
The TCGA prostate cancer cohort dataset was downloaded from cBioPortal. Somatic 
SNPs, INDELs and copynumbervariations of the TCGA cohortandour Sardinian 
cohort were used to identify differential gene mutations, amplifications and deletions 
using the Fisher test. Adjusted P value of less than 0.05 was considered as significant.  
 
12. Differential gene expression and genomic alterations in prostate cancer. 
Differential expression of our candidate driver genes in matched TCGA normal 
samples and GTEx (Genotype-Tissue Expression Project) tissues was performed with 
GEPIA2 [301]. The frequency of the candidate driver alterations in other prostate 
cancer genomic studies was obtained from cbioportal[110].   
 
13. PCR-based ERG fusion detection 
Frequencies of different breakpoints for TMPRSS2-ERG fusions was based on the 
COSMIC database. We designed 5 pairs of primer using Primer5 for detection of the 
amplification and detection of TMPRSS2-ERG fusions based on the top five most 
frequent break points found in the COSMIC database.  DNA of 19 historical paraffin 
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blocks of tumors from Sardinian prostate cancer patients was extracted and used for 
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Chapter Ⅲ . Results: Genomic landscape of Localized Prostate Cancer in a 
Sardinian cohort 
1. General summary of clinical and sequencing parameters 
A total of 30 patients from the Pathology section of the Department of Experimental 
Medicine of the University of Sassari (Sassari, Sardinia, Italy) and diagnosed with 
prostate cancer during 2010 were included in the study. Most patients had levels of 
PSA<10 ng/ml and Gleason scores <=7（low risk, 23 out of 30 patients), six patients 
had PSA levels between 10 ng/mg ~20 ng/ml and Gleason scores<=7 (intermediate 
risk, 6 out of 30), one patient had a Gleason score of 9 (high risk, 1 out of 30). The 
age distribution of the patients ranges from 54 to 74. Among them, 20 patients were 
60~69 years old, four patients were 54 to 59 years old, six patients were 70 to 74 
years old. Survival records show that one patient died within one year after diagnosis, 
while another 4 patients died 5 years after diagnosis. All patients had prostate 
resection. Clinical information is summarized in Table 1. 
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Paired tumor and tumor-adjacent FFPETs sections were obtained from historical 
paraffin blocks of tumors and adjacent normal tissue from resected prostates. DNA 
was extracted from paraffin sections and libraries constructed for whole exome 
sequencing. Sequencing coverage of tumor tissues was between 39-176, with the 
median of 67. The sequencing coverage of histologically normal tissue adjacent to 
tumor tissue was between 30-156, the median was 58 (Figure3.1). 
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Figure 3.1Sequence depth of tumor and tumor adjacent tissues. A) Sequence depth 
distribution of tumor adjacent tissues. B) Sequence depth distribution of tumor tissues. 
 
2. Somatic driver mutations in Sardinia prostate cancer 
To identify somatic mutation in the Prostate Cancer cohort in Sardinia, we sequenced 
the whole exons of paired-samples from 30 patients. Somatic SNPs and Indels were 
called by GATK mutect1 and Pindel respectively. A total of 911 missense SNPs, 37 
splice site mutations, 119 truncating mutations and 140 in-frame indels were 
identified in a total 30 tumor tissues. The number of somatic mutations per patient 
varied from 7 to 114. The median number was 28 mutations per patient. (Figure 3.2) 
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Figure 3.2 Summary of somatic mutation in 30 prostate cancer patients in 
Sardinia. A) Number of somatic mutations in each patient. B)Fraction of six different 
conversions in each sample.C) Overall distribution of six different conversions. D) 
Overall distribution of Transitions and Transversions.E) Oncoplot of gene with 
mutation in at least 3 of the 30 patients. 
 
To identify potential driver mutations, we first mapped all mutations to the 4457 
annotated alterations in the OncoKB database. We found 15 putative driver mutations 
present in 13 genes (Figure 3.3). SPOP -Y87C and KMT2D-TRUNC mutations 
occurred in two samples. Single mutations were found for BRAF-G469A, 
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FLT3-R834Q, APC-TRUNC, BCOR-TRUNC, CDKN2C-TRUNC, 
FBXO11-TRUNC, KEAP1-TRUNC, FBXO11- TRUNC, NF1-TRUNC, 
TP53-TRUNC, RBM10-TRUNC, ZFHX3-TRUNC (Figure 3.5).  
 
 
Figure 3.3 All the 1067 somatic mutations of 30 prostate cancer patients in 
Sardinia were annotated as clinical actionable mutations, putative drivers, 
cancer hot spot mutations and 3D hot spot mutations,respectively.Novel drivers 
were predicted by OncoDrieverCluster. Five mutations are clinical actionable, 15 
mutations are cancer putative drivers (OncoKB annotated alterations). Sixty-five 
mutations are observed in OncokB curated genes and 22 mutations are observed in 
significant mutated genes that predicted by OncoDriverCluster. 
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Figure 3.4 Oncoplot of putative and novel somatic drivers of prostate cancer 
from 30 Sardinian local prostate cancer samples 
wereobtainedbywholeexomesequencingof paired tumorandtumor-adjacent 
tissues. Each green dot represents a patient with a putative missense mutation, black 
dot represents a patient with putative truncating mutation, purple dot represents a 
patient with fusion of the specified gene. 
 
In addition, we found that TP53-F106C was a cancer hot spot mutation and 
FOXA1-S250P was a 3Dhotspot mutation (Figure 3.3). We next mapped these 
mutations to the CIVIC database of actionable mutations and found BRAF- G469A, 
NF1-TRUNC, APC-TRUNC and KMT2D-TRUNC clinically actionable mutations  
(Table2).  
 
Table 2 Clinical actionable mutations in 30 prostate cancer patients  
Patient Gene Type of mutation Drug-Sensitivity 
401 BRAF p.G469A Vemurafenib, Cetuximab, Erlotinib 
202 NF1 p_1172fs Dabrafenib，Binimetinib，JQ1 
202 APC p_1212fs G007-LK,JW55 
303 KMT2D p.GSYTDPYAQPPL2372fs AR-42 
305 KMT2D p.QEPPP2350fs AR-42 
 
To identify potential novel driver candidateswhich were not identified in the OncoKB 
database, we next used the OncoDriverCluster algorithm to predict significantly 
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mutated genes in our cohort. A total of 12 genes including the putative driver SPOP 




Figure 3.5 All the somatic mutations of 30 Sardinian prostate cancer were input 
in OncoDriverCluster algorithm to predict significantly mutated genes in our 
cohort. The y-axis is the log10(fdr), the x-axis represents that the fraction of 
mutations in a particular gene were predicted as cancer driver.  
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Mutations in these 12 genes and mutations in OncoKB curated genes were annotated 
for functional disruption using MutationAssessor, SIFT, Polyphen2, and FATHMM. 
Nine mutations were predicted to be deleterious mutations by at least three methods, 
and four of them were simultaneously predicted to be deleterious mutations by all the 
four methods (Figure 3.6). 
 
Figure 3.6 Four mutations of all the 1067 somatic mutation of 30 Sardinian 
prostate cancer patients have been annotated as damage mutations by all of the 
following, MutationAssessor, SIFT, Polyphen2, FATHMM methods, another 5 
mutations have been annotated as damage by at least three of the four methods. 
 
Six of the 9 domains containing the above mutations have known 3D structures. They 
include, the ALOX12B protein (R422W, Figure 3.7A), the ATAT1 protein (D19V 
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mutation, Figure 3.7B), the ERBB2 Receptor L domain harboring the C53R mutation 
(Figure 3.7C), the ERCC2 protein (R497C mutation, Figure 3.7D), the MAX protein 
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Figure 3.7 A) ALOX12B Lipoxygenase domain R422W mutation.B) ATAT1 D19V 
mutation.C) ERBB2 Receptor L domain C53R mutation.D) ERCC2 R497C 
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mutation.E) FOXA1 Forkhead domain S250P. F) MAX D87N mutation. G) SPOP 
MATH domain Y87C.H) TBX3 T-box V202D mutation. 
 
3. Somatic copy number variation in Sardinia prostate cancer 
Control-Freec was used to analyze somatic copy number variation in paired samples 
of 30 prostate cancer patient in Sardinia. A total of 784 segments of copy number 
variation events were identified, including 9520 gene-level events (2920 gene gains, 
6600 gene losses). We found 444 gene amplifications (copy number variation is 
greater than or equal to 2) and 2135 deletions (copy number variation is less than or 
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Figure 3.8 Control-Freec was used to analyze somatic copy number variation in 
paired samples of 30 prostate cancer patient in Sardinia.Each row represents a 
patient. And the column represents the chromosomes. Each dark red bar represents a 
patient with amplification of the region. Each dark blue bar represents a patient with 
deep deletion of the region. Each light red bar represents a patient with gain of the 
region. Each light blue bar represents a patient with loss of the region. 
 
To identify the copy number variations that may act as “oncogenic drivers”, we first 
mapped copy number variations to the 4457 OncoKB annotated alteration database. 
Six putative oncogene gain events were identified, involving six genes (BCL6, ROS1, 
CDK6, EGRF, ETV1, NTRK1), affecting 5 different tumor samples. Thirty-eight 
putative tumor suppressor gene loss events were identified, involving 30 genes, 
affecting 11 samples. Among them, CDKN1B-loss, DUSP4-loss, and PRDM1-loss 
occurred three times each, and PTEN-loss and RB1-loss occur twice. (Table 3) 
 
Table 3 Clinical actionable copy number variation in 30 prostate cancer patients 
Patient Gene Type of mutation Drug-Sensitivity Drug-Resistance or Non-Response 
815 TYMS Amplification Pemetrexed Pemetrexed 
2154 BRCA1 Deletion Olaparib,CX-5461  
309 EGFR Amplification Cetuximab, Panitumumab Osimertinib, Rociletinib 
309 FBXW7 Deletion Rapamycin (Sirolimus)  
404 NBN Deletion GPI-15427  
305 PTEN Deletion Carboplatin, Buparlisib Everolimus, BYL719 
406 PTEN Deletion Carboplatin, Buparlisib Everolimus, BYL719 
404 RASA1 Deletion Trametinib  
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2154 TSC2 Deletion MTOR Inhibitors  
307 RB1 Deletion Palbociclib（PD0332991)  
404 RB1 Deletion Palbociclib（PD0332991)  
301 STK11 Deletion NA Docetaxel, Selumetinib 
401 ATXN1L Deletion NA Vemurafenib, Dabrafenib 
411 ATXN1L Deletion NA Trametinib 
 
In order to identify new potential driver copy number variation events, we performed 
copy number replay analysis using GISTIC 2.0. A total of 15 significant amplification 
intervals were identified along with the identification of 20 significant loss intervals 
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Figure 3.9G-score across the whole exome region of 30 Sardinian prostate 
cancers. G-scores were calculated by the GISTIC algorithm to determine the 
amplitude and the frequency of copy number variation. 
 
Among the loss intervals, 6q15, 13q21 and 16q24 showed large-scale deletions. 
Further, we found that the 15 significant amplification regions did not contain a 
known onco-gene, but the 20 significant loss regions contained 21 OncoKB curated 
TSGs. Of the total 46 copy number deletion events, 15 deletion events contained 8 
genes that were previously annotated as putative drivers.The other 31 deletion events 
involved 13 curated tumor suppressor genes, including BACH2-loss (4 events), 
NKX3-1-loss(4 events), ATP6V1B2-loss (3 events), EPHA7-loss(3 events), 
ESCO2-loss (3 events), SESN1-loss (3 events), TP63-loss (3 events), ERCC3-loss (2 
events), IRF8-loss (2 events), FAS-loss (1 events), RECQL-loss (1 events), 
SDHC-loss (1 events), TBL1XR1-loss (1 events) (Figure 3.10).  
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Figure 3.10Oncoplot of amplifications in oncogenes and deletion in tumor 
suppressor genes. Each red bar represents a patient with amplification of the 
specified gene on the left. Each blue bar represents a patient with deep deletion of the 
specified gene. 
 
We also examined the frequency of the deletion of the genes outlined above in other 
prostate cancer genomic studies and found that IRF8-loss occurred in 2-8% of 
prostate cancer patients [104, 254, 302-305](Figure 3.11). Patients with IRF8-loss 
have worse survival outcome compared with patients without IRF8-loss (Figure 3.12). 
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Figure 3.11 Frequencies of IRF8 deletion across the prostate cancer genomic 
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Figure 3.12 Patients with IRF8 deletion have decreased survival. 
 
4. Comparison of gene mutations between prostate cancer in the TCGAdatabase 
and Sardinia cohort 
To identify similarities and differences in prostate cancer mutations between Sardinia 
and patients of North America European ancestry, we had integrated the somatic 
mutation and copy number variation data from our Sardinian cohort and made a 
gene-level comparison to the TCGA prostate cancer dataset. The results reveal that 
MUC4, PRG4,DSPP SNPs and indels, 4q13.2 (UGT family genes) and 4q16.3 
(ZNF595, ZNF718) amplifications, 8q23.1 (USP17L1/2/3) and 4q35.2 (DUX4) 
deletions are significantly enriched in the Sardinian prostate cancer cohort compared 
to the TCGA cohort (Fisher test, adjusted p value<0.05)(Figure 3.13-3.15). We also 
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observed that both the Sardinian cohort and the TCGA data set had similar 
frequencies and types of tumor suppressor gene deletions (Figure 3.15). MUC4 and 
PRG4 are large glycoprotein and mutations in them are possible passengers. The 
4q16.3 amplification and 4q35.2 deletion only affect very small region of the 
chromosome. 8q23.1 deletion overlap with TCGA 8q23.1 deletion but have border 
expansion. 4q13.2 amplification including multiple UGT family members (Figure 4.1). 
The pick gene is UGT2B4 which is tend to have high expression in TCGA tumor 
samples rather than normal samples(Figure 4.3) and patients the high expression of 
UGT2B4 have better disease-free survival (p=0.047) (Figure 3.17). Co-expression 






Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 




Figure 3.13 The TCGA prostate cancer cohort dataset was downloaded from 
cBioPortal. Somatic SNPs, INDELs of the TCGA cohortandour Sardinian cohort 
were used to identify differential gene mutations frequencies using the Fisher test. 
Adjusted P value of less than 0.05 was considered as significant.Mutations in MUC4, 
PRG4 and DSPP are significantly increased in Sardinia prostate cancer cohort 
compared to the TCGA cohort (p value < 0.05). 
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Figure 3.14 The TCGA prostate cancer cohort dataset was downloaded from 
cBioPortal. Amplifications of the TCGA cohortandour Sardinian cohort were used to 
identify differential gene mutations, amplifications frequencies using the Fisher test. 
Adjusted P value of less than 0.05 was considered as significant. 4q13.2 and 4q16.3 
amplifications are significantly greater in the Sardinia prostate cancer cohort 
compared to the TCGA cohort (p value < 0.05). 
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Figure 3.15 The TCGA prostate cancer cohort dataset was downloaded from 
cBioPortal. Amplifications of the TCGA cohortandour Sardinian cohort were used to 
identify differential gene mutations, deletions frequencies using the Fisher test. 
Adjusted P value of less than 0.05 was considered as significant. 8p23.1 and 4q35.2 
deletions are significant greater in the Sardinia prostate cancer cohort compared to the 
TCGA cohort (p value < 0.05). 
 
To further understand the potential impact of these genes on tumor development, we 
examined the gene expression profiles in the TCGA and the Genotype-Tissue 
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Expression (GTEx) databases for differential expression between prostate tumors and 
normal tissue. Expression profiles revealed that MUC4 is significantly 
down-regulated in prostate cancer tissue (Figure 3.16). Furthermore, patients with 
high expression of PRG4 have poorer disease-free survival (Figure 3.17) compared to 
patient with tumors having lower expression of PRG4. These indicate that mutations 
in MUC4 and PRG4 may be more than just passenger mutations. UGT gene cluster 
represents a family of glycosyltransferases which are able to transfer estradiol to 
estradiol glucuronide and are involved in the regulation of estrogen metabolism 
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Figure 3.16MUC4 is significantly down-regulated in prostate cancer tissues 
(GEPIA dataportal). Expression of MUC4 was determined in 43 normal (green bar) 
and 497 prostate cancers (red bar) from the TCGA database. MUC4 was found to be 
significantly upregulated (p<0.05) in localized prostate tumors compared with tumor 




Figure 3.17 Low expression of PRG4 have better disease-free survival (GEPIA 
dataportal) compared to normal expression.All the 497 TCGA localized prostate 
cancer patients were divided into a PRG4 low expression group and a PRG4 high 
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expression group based on the PRG4 median expression. Between-group comparisons 





Figure 3.18 UGT family is important genes in super pathway of estrogen 
metabolism.(https://pathcards.genecards.org/card/estrogen_metabolism) 
 
5. Novel BTBD7-SLC2A5 fusions and ETS family status in prostate cancer of 
Sardinia 
We next used FusionMap to identify fusion events in whole exome data. We detected 
15 in-frame fusions and 44 out of frame fusion genes in the 30 patients. Of the fusion 
events, only two pairings, MAGOH->TMEM220 (out of frame) and 
BTBD7->SLC2A5 (in frame), occurred in more than one sample, 5 and 4 times 
Tiansheng Zeng 
Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 
University of Sassari 
86 
respectively (Figure 3.19).BTBD7-SLC2A5 contains exons 1-10 of BTBD7 and 
exons 2-8 of SLC2A5. N-terminus of the fusion protein contains the BTB/POZ 
domain of BTBD7, and the C-terminus contains Transmembrane region of SLC2A5 




Figure 3.19 Oncoplot of fusion genes that are altered in more than 2 or more 
patients (ERG fusions were detected based on PCR methods and the remaining 
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Figure 3.20 Predicted transcript and protein of the BTBD7-SLC2A5 fusion 
determined by Fusion hub. The predicted protein contained the entire 
transmembrane domain and fructose transporter domain of SLC2A5 and the BTB 
domain of BTBD7. 
 
ETS family fusions are the most common fusion event associated with prostate cancer. 
ERG-TRMPSS2 gene fusions are found in 46% of prostate cancers, followed by 
ETV1 fusions in 8% and ETV4 fusions in 1% of the patients [254]. In our whole exon 
data of 30 Sardinian prostate cancer patients, none of the ETS fusions was detected. 
Possibly due to the low sensitivity of whole exon data to detect fusion events, we also 
used PCR to detect ERG fusions at the RNA level in 19 samples. ERG fusions were 
detected in only two of the 19 samples (11%) (Figure 3.19). The frequency of ERG 
fusion is still lower than the expected frequency found in patients with European 
ancestry. However, we did observe a significant deletion of 22q23.1 in the copy 
number reoccurring analysis (Figure 3.9 & Figure 3.15). Considering the ERG 
fusion event is often co-occurrence with ERG deletion, the frequency of ERG fusion 
events in Sardinia prostate cancer may be higher at 11%. 
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6. Germline risk mutations in the patients 
In order to identify germline risk mutations for prostate cancer in the Sardinian 
prostate cancer cohort, we used the GATK best practice pipeline to perform germline 
SNP and INDEL calling with fastq files that generated from tumor adjacent tissue. 
We filtered out the mutations with a calling quality less than 200 and MAF>0.1. The 
remaining mutations were evaluated for the effect on protein structure/function using 
MutationAssessor, SIFT, Polyphen2, and FATHMM. A total 113 mutations were 
annotated as deleterious mutations by all the four methods Among these, we found a 
variation in ARSD-G320D (Figure 3.21 & Figure 3.22) affecting 53% of the patients 
and that in CNN2-G250V-G263S (Figure 3.21 & Figure 3.22) affecting 9% of the 
samples. In addition, four genes that were previously recorded in the Family cancer 
database, which contains approximately 500 cancer related hereditary disorders, have 
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Figure 3.21 Oncoplot of germline risk mutations. Each green dot represents a 
patient with a germline missense mutation in a specified gene on the left. 
 
We next examined expression of ARSD and CNN2 in prostate cancer by looking at 
prostate cancer gene expression profiles in the TCGA and the Genotype-Tissue 
Expression (GTEx) databases. We found that ARSD tends to be highly expressed in 
tumor tissues (data not show). Patients with high expression of ARSD have better 
disease-free survival than those with lower expression of ARSD (Figure 3.23).  
 
Tiansheng Zeng 
Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 




Figure 3.22 A) ARSD Sulfatase domain with the G320D mutation.B) CNN2 calponin 
domain with G250V and G263S mutations. 
 
Considering that ARSD regulates estrogen metabolism (Figure 3.25), it is possible 
that tumors with high ARSD expression or expressing variants of ARSD impact 
castration therapy (homo-therapy) hence leading to better or differential (variant) 
disease-free survival. CNN2 is significantly down-regulated in tumors compared to 
normal tissue acting as a possible tumor suppressor gene (Figure 5.24). These results 
indicate that ARSD and CNN2 germline mutations are potentially associated with 
prostate cancer development or therapeutic impact in Sardinia.  
 
Tiansheng Zeng 
Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 




Figure 3.23 Patients with high ARSD expression have better disease-free survival 
(GEPIA dataportal). All the 497 TCGA localized prostate cancer patients were 
divided into a ARSD low expression group and a ARSD high expression group based 
on the ARSD median expression. Between-group comparisons of DFS were 
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Figure 3.24 CNN2 significantly down-regulated in prostate cancer tissues 
(GEPIA dataportal). Expression of CNN2 was determined in 43 normal (green bar) 
and 497 prostate cancers (red bar) from the TCGA database. CNN2 was found to be 
significantly upregulated (p<0.05) in localized prostate tumors compared with tumor 
adjacent normal tissue. 
 
Moreover, the data show that there is a tendency of mutual exclusivity (p=0.062) 
between the germline risk variants ARSD-G320D and somatic UGT family 
amplification (Figure 5G). 
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Emerging evidence indicates that there are remarkable disparities in prostate cancer 
epidemiology as well as the molecular landscape among different ethnic groups of 
European, North America African and Asian origin [4, 133]. The Sardinia population 
is an isolated Mediterranean population with evolutionary divergence from the 
European mainland population taking place some 143.3±1.3 generations in the past. 
Furthermore, prostate cancer incidence is lower in the Sardinia population compared 
with mainland Europe [281, 282]. However, the genomic landscape of prostate cancer 
in Sardinia is unknown. We performed whole exome sequencing on tumor and 
tumor-adjacent tissues from 30 patients diagnosed with local prostate cancer to reveal 
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germline risk variants, and identify somatic SNPs, INDELs, copy number variations, 
and fusion events in prostate cancers. Our data show both genomic disparities and 
similarities between prostate cancer in our Sardinian cohort and prostate cancers 
reported in the TCGA European ancestry cohort.  
 
ERG gene family fusions are detected in approximately 50% of patients with 
European ancestry. However, recent studies show that the incidence of ERG fusion 
are lower in patients of North America African (20-30%) and Asian (8%-22%) 
ancestry [305, 309, 310]. We were unable to detect ERG fusion events in Sardinia 
prostate cancer cohort by whole exome sequencing, although we did detect 2 out of 
19 (11%) patients having ERG fusion when using a PCR based method. ERG fusion 
events are accompanied with ERG loss on Chromosome 21q22.3 [311]. Nevertheless, 
we only observed ERG loss in only 7% of our Sardinia cohort compared to 15% 
reported in the TCGA cohort (most of ERG fusions occur in RNA level). Our data 
indicates a lower frequency of ERG-fusion events in Sardinia cancer patients. 
 
We did find, however, a novel fusion event, BTBD7-SLC2A5, in 12% of the 
Sardinian patients. In addition, we didfind a novel fusion event, BTBD7-SLC2A5, in 
12% of the Sardinian patients, whose breakpoints were within an exon region (Figure 
6A). BTB/POZ domain-containing protein 7 (BTBD7) BTBD7 regulates the 
dynamics of cell adhesion and motility during epithelial branching 
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morphogenesis[312], and has been reported to be associated with various 
cancers[313-315]. BTBD7 fusions were also observed in the TCGA pan-cancer 
cohort. BTBD7-UBR7 and UBR7-BTBD7 were observed in breast cancer, 
BTBD7-RGS9 fusion in Ovarian Cancer, and TARBP1-BTBD7 fusion in Lung 
Adenocarcinoma (http://www.cbioprotal.org/). However, each of those fusions 
were detected only in a single patient. In our study, BTBD7 fusion with the fructose 
transporter SLC2A5 was observed in four of the prostate cancer patients in Sardinia, 
indicating BTBD7 fusion can be observed more frequently in tumors in a specific 
population.  
 
SLC2A5 is a fructose transporter and has been reported to be associated with various 
cancers as well[316-318]. Lung cancers with mutations in SLC2A5 promote lung 
adenocarcinoma cell growth and metastasis by enhancing fructose utilization[317]. 
BTBD7-SLC2A5 fusions that identified in this study contained entire transmembrane 
domain and fructose transport domain of SLC2A5 may be involved in shifting of 
energy metabolism to enhance tumor growth. However, further investigated in the 
future is needed to determine the importance of this fusion. 
 
BTBD7-SLC2A5 may also be involved in unregulated cell adhesion and motility or 
epithelial morphogenesis due to loss of exons 10 and 11. Functional studies will aid in 
uncovering the functional consequences of this fusion event. 
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Meanwhile, we found that 20% of the Sardinia samples had amplification of UGT 
family while only 0.3% in of the TCGA cohort had amplification in this region. UDP 
glucuronosyltransferase family genes catalyze the addition of the hydrophilic moiety, 
glucuronide, to acceptor molecules in a process called glucuronidation[319, 320]. In 
humans there are two major classes of UDP glucuronosyltransferase, UGT1 and 
UGT2, each of which contains multiple genes on chromosome 2 and 4, respectively. 
In Sardinian prostate cancers we observed an amplification in chromosome 4q13.2 
which contains multiple UGT2 genes (Figure4.1). 
 
 
Figure 4.1 Oncoplotof amplifications of genes in Chromosome 4q13.2 across 30 
Sardinian prostate cancer patients. Each red bar represents a patient with an 
amplification of the specified gene on the left. 
Tiansheng Zeng 
Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 
University of Sassari 
97 
 
Within this amplified region the genes UGT2B7, UGT2B15, UGT2B17 and 
UGT2B28 have been broadly investigated in prostate cancer because of their ability to 
inactive DHT and testosterone[321].  Germline inactivating mutations including 
deletion/insertion mutations or single nucleotide polymorphisms of these genes 
increases prostate cancer risk by presumably increasing levels of unconjugatedactive 
androgens either systemically (due to reduced hepaticmetabolism), or locally in the 
prostate, or both[321]. However, a number of studies haveexamined the relationship 
between UGT2B15 andUGT2B17 expression levels and prostate cancer progression. 
One study reported that UGT2B17 protein level wasincreased in prostate cancer 
relative to BPH, and it wasmore abundant in metastatic than benign tumors[322]. 
Another study reportedthat higher UGT2B17 protein levels were associated with 
higherGleason scores, metastasis, and progression to CRPC[323].Moreover, 
UGT2B17 overexpression was associated withincreased risk of biochemical 
recurrence during androgendeprivation therapy[324]. Recent work has identified a 
novel function for UGT2B17 in androgen-independent AR signaling related to the 
activity of c-Src kinase[323]. In contrast, UGT2B15 protein levels were reduced in 
prostate tumors relative to BPH. To examine the impact of UGT2B15 expression in 
prostate cancer, we investigated the expression data of the 497 prostate cancer 
patients from TCGA. Our analysis showed that the expression level of UGT2B15 in 
tumors had a tendency to be lower than normal tissues (but not significantly lower), 
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although, UGT2B15 was similar to UGT2B17, patients with higher expression of 
UGT2B15 had increased risk of biochemical recurrence (Figure 4.2). These analyses 
suggest that high expression of UGT2B15 and UGT2B17 in the tumors had additional 
functions other than DHT and testosterone metabolism[323].  
 
 
Figure 4.2 Patients with high expression of UGT2B15 had reduced disease-free 
survival compared with those patients with low expression of UGT2B15.  A) All 
the 497 TCGA localized prostate cancer patients were divided into UGT2B15 a low 
expression group and a UGT2B15 high expression group based on the UGT2B15 
median expression. B) Between-group comparisons of DFS were performed by the 
Kaplan-Meier method and the log-rank test. 
 
UGT2B4 was identified as the peak of amplification in the UGT family in our present 
study. Interestingly, UGT2B4 is noticeable for its ability in the clearance of 
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estrogens[325]. It was reported that polymorphisms of UGT2B4 have been associated 
withincreased breast cancer risk[326]. To examine the impact of UGT2B4 expression 
in prostate cancer, we investigated the expression data of pan-cancer study from 
TCGA. Our analysis showed that the expression level of UGT2B4 in tumors of breast 
cancer was significantly lower than normal tissues while UGT2B4 was significantly 




Figure 4.3 Expression of UGT2B4 was determined in 43 normal (green bar) and 
497 prostate cancers (red bar) from the TCGA database. UGT2B4 was found to 
be significantly upregulated (p<0.001) in localized prostate tumors compared with 
tumor adjacent normal tissue 
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Figure 4.4 Spearman rank correlation analysis was performed on expression 
profiles of tumor tissues of 497 TCGA localized prostate cancer patients and 
UGT2B4. 1165 genes were positively co-expressed with UGT2B4 and 868 genes 
were negatively co-expressed with UGT2B4 i. (Spearman correlation >0.1, p<0.01) 
 
To further examine the potential function of the UGT2B4 in prostate cancer, we 
performed the spearman correlation analysis of UGT2B4 in the expression data of the 
497 prostate cancer patients from TCGA. We found that UGT2B4 expression was 
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associated with increased expression of genes that were found enriched in glutamine 
and monocarboxylic acid metabolic pathways. (Figure 4.4-Figure 4.7). 
 
 
Figure 4.5 Thirty-seven curated oncogenes and tumor suppressor genes were 
correlated with UGT2B4 in the spearman rank correlation analysis. Heatmap of 
hierarchal clustering of patients based on expression of UGT2B4 and 37 UGT2B4 
co-expressed oncogenes and tumor suppressor genes was described using a function 
Heatmap in ComplexHeatmap R package. Patients were split by median expression of 
UGT2B4 before hierarchal clustering. There was a cluster of prostate cancer patients 
with high expression of UGT2B4, SPINK1, SRC. 
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Thehigh frequently of somatic UDP-glucuronosyltransferase gene family 
amplification on Chromosome 4q13.2 in Sardinian prostate cancers may promote 
tumorigenesis and development by upregulating the expression of UGT2B4 and 
UGT2B7/15/17. Upregulation of these genes may homeostatically maintain the 
crosstalk of AR and ER signaling[327, 328] or other metabolic signaling pathways 




Figure 4.6 Functional enrichment including GO Biological Processes, KEGG and 
Reactome pathways (http://www.metascape.com/) reveals that genes 
co-expressed with UGT2B4 in the spearman correlation analysis were 
functionally enriched in ribonucleoprotein complex biogenesis, as well as 
glutamine, nucleotide and monocarboxylic acid metabolic pathways 
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Another possibility is that UDP glucuronosyltransferase family amplification is 
related to their important role in detoxification of xenobioticsubstrate[329]. Prostate 
cells with increased expression of UDP glucuronosyltransferase may have provided 
enhanced fitness against Sardinian environmental xenobiotic toxins. 
 
 
Figure 4.7 PPI network of UGT2B4 co-expression genes in prostate 
cancerProtein-Protein interaction network of UGT2B4 co-expressed genes were 
downloaded from InWeb_IM (https://www.intomics.com/) and visualized by 
Cytoscape.UGT2B4 positive co-expression genes that broadly interact with SRC and 
MYC, functionally clustered in ribosome biogenesis, functionally clustered in 
nucleobase biosynthesis monocarboxylic acid metabolism, and Carbohydrate 
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metabolic are highlighted in red. Genes that negative co-expressed with UGT2B4 
clustered in synapse organization and are blue highlighted. 
 
In addition, we found that IRF8-loss occurred in 6% of Sardinia prostate cancer and in 
2-8% of prostate cancer patients across multiple prostate cancer genomic studies [104, 
254, 302-305](Figure 3.9). In the most recent genomic study of mCRPC, data show 
that patients with IRF8-loss have poorer survival outcome compared with patients 
without IRF8-loss, indicating IRF8 is an important tumor suppression gene in prostate 
cancer.  
 
IRF8 (also ICSBP) is a transcription factor that is a member of the interferon 
regulatory protein family (IRF)[330]. IRF8 is predominantly expressed in 
hematopoietic stem, progenitor and terminally differentiated cells including myeloid, 
NK and dendritic cells [331]. IRF8 functions as a transcriptional activator and 
repressor that is required to mediate immune cell differentiation and execution of 
cell-type-specific gene expression programs [332]. IRF8 also regulates the expression 
of genes involved in several cellular functions including adaptive immunity, cell cycle 
regulation and apoptosis [333, 334]. Loss of IRF8 in murine models results in a 
hematopoietic malignancy, in part due to STAT5 repression of IRF8 tumor 
suppressive activity [335]. Homozygous biallelic IRF8 mutations have been identified 
in NK deficiency syndromes and IRF8 missense mutations have been identified in 
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dendritic cell deficiency syndromes, suggesting IRF8 is required for functional NK 
and dendritic cell development [336]. Somatic hotspot mutations in the IRF8 DNA 
binding domain have been identified in pediatric-type follicular lymphoma [337] and 
in diffuse large B cell lymphoma[338]. In addition, IRF8 downregulation is found in 
hematopoietic malignancies due to epigenetic and signaling dysregulation [335, 339]. 
Even though the role of IRF8 in immunity has been widely investigated and the its 
somatic mutations have been identified in lymphoma, its role in prostate cancer is still 
unknown. 
 
In keeping with several studies on prostate cancer we identified somatic mutations in 
TP53, SPOP, KMT2D, FOXA1 and copy number loss of NXK3-1, PTEN, RB1, 
PCDH9. These mutations are well recognized as important drivers of prostate cancer 
across multiple ethnic groups [113, 254, 305, 309].  
 
Early genetic quantitative studies of identical and fraternal twins have demonstrated 
that the heritability of prostate cancer is 42% - 58%, higher than that of any other 
malignant tumors[52, 340]. Todate, 167 prostate cancer risk loci have been identified 
by genome-wide association analysis [70]. These loci with high frequency and low 
penetration in the population explain only about 19% of the familial risk of prostate 
cancer. In recent years, the effect of variants with low frequency and high penetration 
on prostate cancersusceptible genes has become clear, such as HOXB13, 
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BRCA1/BRCA2, DNA mismatch and other DNA repair pathway[72]. These variants 
explained only about 5% of the family risk of prostate cancer.Where is the missing 
heritability of prostate cancer? 
 
In addition, in United States, the incidence and mortality of prostate cancer varies 
considerably by races and ethnicities [7, 8]. The prostate cancer incidence of the 
North AfricanAmerican is 208.7 per 100,000 and the mortality is 47.2 per 100,000, 
while prostate cancer incidence in the Asian American, Native Hawaiian and Pacific 
Islander (AANHIP) is only 67.8/100000 which is almost one third of North America 
Africans, and one half of Non-Hispanic Whites (123/100000)[8]. Even removal of 
effects of other factors, racial disparities in prostate cancer incidence in United State 
remain significant. 
 
Therefore, racial geneticdisparity is one of the major factors contributing to the 
variability in the incidence of prostate cancer. Even though multiple large multi-ethnic 
genome-wide association studies focused on identification of ethnic specific risk locus 
for prostate cancer, they are insufficient to explain all of the racial disparity [119, 341]. 
Where is the missing racial genetic disparity on prostate cancer? 
 
One of the reasons for the missing heritability and racial genetic disparity of prostate 
cancer is that most studies are based on GWAS or Whole exome sequencing which 
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underrepresent the full genome and epigenetic factor. The other possible reason is that 
the prostate cancer risk variants are too rare to be significantly identified. Even though 
almost 20 susceptible gene have been identified [49], we are still not able to identify 
the frequency of most of the specific mutations in different populations because they 
are very rare. Recently there are other bolder speculations that environmental factors 
can alter the epigenome and can be inherited in future generations [342]. If this is the 
case, studies based on GWAS and WGS and WES only focus on nucleotides, and do 
not examine markers of epigenetic heritability [343] However, the current evidence is 
not sufficient to indicate that the epigenome play a significant role in prostate cancer 
heritability.  
 
The racial mixing and the underrepresentation from racial and ethnic minorities in 
current studies are possible reasons as well. In 1795, Johann Friedrich Blumenbach 
defined the different races of mankind. So far, the scientific community still adopts a 
similar fuzzy definition, which cannot accurately distinguish races, especially when 
racial mixing is becoming more common. In addition, most of the prostate cancer 
genomic studies are based on the Caucasian cohorts. The insufficient number of 
specimens from African Americanmen and other minority populations, together with 
the heterogeneity in the molecular etiology of prostate cancer across populations, 
challenge the generalizability of findings from these projects [133]. 
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In the 30 Sardinian prostate cancer patients, we have identified 106 potential germline 
risk variants on 82 genes with five of the genes having been previously demonstrated 
to be associated with familial cancers. Significantly, ARSD-G320D variants were 
observed in 53% of the Sardinian patients. If there are germline prostate cancer risk 
variants in the Sardinian population, it would be striking as the highest frequency of 
germline risk variants were observed in HOXB13 G84E which only occurred in about 
1~2% of unselected Nordic patients [344].  
 
Even though we cannot exclude the ARSD G320D variants, as ARSD have been 
demonstrated to be associated with estrogen metabolism which strongly affects 
prostate cancer. ARSD transforms the storage form of estrogen (estrogen sulfate) to 
act estrogen(https://pathcards.genecards.org/card/estrogen_metabolism). 
Evidence that supports estrogen as a prostate cancer-causing agent includes 
association of elevated levels of estrogen with prostate cancer, changes in estrogen 
receptor status in advanced prostate cancer, and rodent models and chimeric human 
tissue graft models showing induction of prostate cancer using estrogen plus 
testosterone. Based on our data in this study, it is still difficult to link the 
ARSD-G320D as a risk variant for prostate cancer in Sardinia. A larger cohort and a 
more focused study will help resolve these questions. 
 
Tiansheng Zeng 
Genomic Landscape of Local Prostate Cancer in Sardinia Population 
PhD school in Life Science and Biotechnologies 




Overall, our data revealed the similarities and disparities of the molecular basis of 
prostate cancer between Sardinians and other ethnic groups (Table4.1). The 
understanding of the genomic landscape of prostate cancer in different ethnic 
populations will give help in the application of precision medicine in Sardinian 
patients. The novel drivers we identified in prostate cancer in our Sardinian cohort are 
potential drug targets. Further understanding their functional mechanism of action 
will aid in developing drugs to benefit the patients. To achieve these goals, in the 
future, a retrospective research study with a larger cohort with prognosis information 
is necessary to investigate the clinical relevance of these gene aberrations in Sardinian 
prostate cancer. Furthermore experiments in vivo and vitro should be engaged to 
determine the biology and targetability for these genes. 
 
Conclusion and prospect 
We analyzed both germline variation and somatic mutations of 30 Sardinian prostate 
cancer patients and identified a novel Germline risk mutation ARSD-G320D 
occurring in 53 percent of the patients. We also found somatic UGT family 
Table 4.1 Important gene  aberrations that enriched in Sardinian prostate cancer 
Gene_Symbol Aberration Type Frequency
UGT famlily Amplification Somatic 20%
ARSD G320D Germline 53%
BTBD7-SLC2A5 Fusion Somatic 12%
CNN2 G250V&G263S Germline 9%
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amplifications which occurred in 20% the patients. Interestingly, both ARSD and 
UGT family members regulate estrogen metabolism. A link between estrogen 
metabolism and prostate cancer is well established [307, 345, 346]. In addition, we 
identified 15 putative and 9 novel candidate driver mutations, 44 putative copy 
number driver events and another 31 tumor suppressor gene deletion events on 11 
tumor suppressor genes. We pointed out that IRF8 deletion in 16q24.2 is a candidate 
driver in prostate cancer and patients with IRF8 deletion have worse prognosis. 
Finally, we identified one candidate out of frame fusion MAGOH-TMEM220 and one 
candidate in-frame fusion BTBD7-SLC2A5 occur in 15% and 12 % of the patients 
respectively. Our data revealed similarities and disparities of the molecular basis of 
prostate cancer between Sardinians and other ethnic groups and will benefit the 
prostate cancer risk monitoring and treatment management and development in 
Sardinia. 
 
A brief summary of the Chinese prostate cancer study 
To broaden our understanding of ethnicity and prostate cancer we conducted a WES 
study on a cohort of Chinese prostate cancer patients. In the Chinese prostate cancer 
cohort, we have seen greater molecular disparities from TCGA cohort than in the 
Sardinian prostate cancer cohort. In the Chinese study, we have sequenced tumors of 
144 Chinese prostate cancer patients and identified 38 genes significantly mutated 
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genes. Interestingly, 20 of them have not been implicated in prostate cancer in 
Caucasians studies. These genes include nucleoporin 93, and cyclin D2. (Figure 5.1). 
Comparing Chinese and Caucasian prostate cancer reveals a set of genomic markers 
that may be informative for ethnic disparities. (Figure 5.2 & Figure 5.3). These 
genomic markers are summarized in Table 5.1. 
 
 
Figure 7.1 Oncoplot of 38 somatic drivers of prostate cancer from 144 Sardinian 
prostate cancer patients. * Novel identified drivers in prostate cancer of Chinese. 
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Figure 7.2 Comparison of Chinese and Caucasian prostate cancer with somatic 
mutations. 
 
Overall，comparison of Chinese and Caucasian prostate cancer genome reveals a great 
ethnic disparities and once again emphasize the challenge toa compressive 
understanding of genetic risk and precision medicine of prostate cancer patients 
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Data and material accession numbers 
All data are available in NCBI, under study accession number: PRJNA546032. 
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Abbreviations  
HPV Human papillomavirus 
CMV Cytomegalovirus 
HSV2 Human herpes simplex virus type 2 
HHV8 Human herpesvirus type 8 
EBV Epstein-Barr virus 
HPC1 Hereditary prostate cancer 1 
GWAS genome-wide association analysis 
mCRPC Metastatic castration resistance prostate cancers 
MSI Microsatellite instability 
ROS Reactive oxygen species 
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TNF Tumor necrosis factor 
PIA Proliferative inflammatory atrophy 
EMT Epithelial to mesenchymal transition 
PAP Prostatic acid phosphatase 
TRUS Transrectal ultrasound 
HK2 Human kallikrein 2 
PHI Prostate health index 
FDA Food and Drug Administration 
AUC Area under the curve 
DRE Non-digital rectal exam 
CRPC Castration resistant prostate cancer 
OS Overall survival 
PFS Progression-free survival 
ADT Androgen deprivation therapy 
GnRH Gonadotropin-Releasing Hormone 
LHRH Luteinising-hormone releasing hormone 
LH Luteinizing hormone 
ACTH Adreno-cortico-tropic-hormone 
AR Androgen receptor 
DBD DNA binding domain 
LBD Ligand binding domain 
NTD N-terminal domain 
PROTAC Proteolysis Targeting Chimera 
PARP Poly ADP-ribose polymerase 
CXCR2 Chemokine-chemokine receptor 
PIN Prostatic intraepithelial neoplasia 
HGSOC High-grade serous ovarian cancer 
GOF Gain-of-function 
APC Adenomatous polyposis coli 
ERK Extracellular signal-regulated kinase 
FFPET Formalin-fixed paraffin-embedded tissue 
BWA Burrows-Wheeler Aligner 
ESP Exome Sequencing Project 
GTEx Genotype-Tissue Expression Project 
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